CA3021944A1 - Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them - Google Patents
Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- CA3021944A1 CA3021944A1 CA3021944A CA3021944A CA3021944A1 CA 3021944 A1 CA3021944 A1 CA 3021944A1 CA 3021944 A CA3021944 A CA 3021944A CA 3021944 A CA3021944 A CA 3021944A CA 3021944 A1 CA3021944 A1 CA 3021944A1
- Authority
- CA
- Canada
- Prior art keywords
- complex
- ivacaftor
- recited
- disease
- vinylpyrrolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 title claims abstract description 202
- 229960004508 ivacaftor Drugs 0.000 title claims abstract description 196
- 238000000034 method Methods 0.000 title claims abstract description 56
- 230000008569 process Effects 0.000 title claims abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 26
- 150000003839 salts Chemical class 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 143
- 238000009472 formulation Methods 0.000 claims abstract description 112
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 49
- 230000035699 permeability Effects 0.000 claims abstract description 36
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 34
- 238000010668 complexation reaction Methods 0.000 claims abstract description 29
- 230000009246 food effect Effects 0.000 claims abstract description 19
- 235000021471 food effect Nutrition 0.000 claims abstract description 19
- 229920001577 copolymer Polymers 0.000 claims description 72
- 239000000243 solution Substances 0.000 claims description 72
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 68
- 229940117958 vinyl acetate Drugs 0.000 claims description 68
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 67
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 66
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 41
- 229910001868 water Inorganic materials 0.000 claims description 39
- 229920001983 poloxamer Polymers 0.000 claims description 35
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 238000013149 parallel artificial membrane permeability assay Methods 0.000 claims description 27
- 239000007787 solid Substances 0.000 claims description 26
- 239000008187 granular material Substances 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 21
- 239000000084 colloidal system Substances 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 21
- -1 poly(2-ethyl-2-oxazoline) Polymers 0.000 claims description 21
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims description 16
- 230000001404 mediated effect Effects 0.000 claims description 15
- 201000009266 primary ciliary dyskinesia Diseases 0.000 claims description 15
- 239000006185 dispersion Substances 0.000 claims description 14
- 239000007962 solid dispersion Substances 0.000 claims description 13
- 208000025678 Ciliary Motility disease Diseases 0.000 claims description 12
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 12
- 201000010064 diabetes insipidus Diseases 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 229960000502 poloxamer Drugs 0.000 claims description 12
- 239000008139 complexing agent Substances 0.000 claims description 11
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 10
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 229920002554 vinyl polymer Polymers 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 229960004106 citric acid Drugs 0.000 claims description 9
- 238000001228 spectrum Methods 0.000 claims description 9
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 8
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 8
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 8
- 238000004090 dissolution Methods 0.000 claims description 8
- 229910016860 FaSSIF Inorganic materials 0.000 claims description 7
- 229910005429 FeSSIF Inorganic materials 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 7
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 7
- 229960003194 meglumine Drugs 0.000 claims description 7
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 7
- 239000001632 sodium acetate Substances 0.000 claims description 7
- 235000017281 sodium acetate Nutrition 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 206010067265 Heterotaxia Diseases 0.000 claims description 6
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 6
- 206010033645 Pancreatitis Diseases 0.000 claims description 6
- 238000001069 Raman spectroscopy Methods 0.000 claims description 6
- 208000031733 Situs inversus totalis Diseases 0.000 claims description 6
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 208000008797 situs inversus Diseases 0.000 claims description 6
- 229960004249 sodium acetate Drugs 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims description 5
- 239000012861 aquazol Substances 0.000 claims description 5
- 229920006187 aquazol Polymers 0.000 claims description 5
- 229920001400 block copolymer Polymers 0.000 claims description 5
- 150000005690 diesters Chemical class 0.000 claims description 5
- 125000005456 glyceride group Chemical group 0.000 claims description 5
- 229920000578 graft copolymer Polymers 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- 239000011976 maleic acid Substances 0.000 claims description 5
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 230000000112 colonic effect Effects 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 4
- 230000001603 reducing effect Effects 0.000 claims description 4
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 claims description 3
- 102100034452 Alternative prion protein Human genes 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 102100032187 Androgen receptor Human genes 0.000 claims description 3
- 208000009575 Angelman syndrome Diseases 0.000 claims description 3
- 206010002961 Aplasia Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 208000012904 Bartter disease Diseases 0.000 claims description 3
- 208000010062 Bartter syndrome Diseases 0.000 claims description 3
- 208000006386 Bone Resorption Diseases 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 208000031976 Channelopathies Diseases 0.000 claims description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 206010062264 Congenital hyperthyroidism Diseases 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 208000024940 Dent disease Diseases 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 206010013883 Dwarfism Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 208000024720 Fabry Disease Diseases 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 208000019683 Gorham-Stout disease Diseases 0.000 claims description 3
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 3
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims description 3
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims description 3
- 201000000101 Hyperekplexia Diseases 0.000 claims description 3
- 206010058271 Hyperexplexia Diseases 0.000 claims description 3
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 3
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims description 3
- 208000000038 Hypoparathyroidism Diseases 0.000 claims description 3
- 208000003892 Kartagener syndrome Diseases 0.000 claims description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 3
- 208000007466 Male Infertility Diseases 0.000 claims description 3
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 3
- 208000008955 Mucolipidoses Diseases 0.000 claims description 3
- 206010072928 Mucolipidosis type II Diseases 0.000 claims description 3
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 3
- 208000010316 Myotonia congenita Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 3
- 206010049088 Osteopenia Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000035467 Pancreatic insufficiency Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000025237 Polyendocrinopathy Diseases 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 201000005660 Protein C Deficiency Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000035954 Thomsen and Becker disease Diseases 0.000 claims description 3
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 3
- 208000004622 abetalipoproteinemia Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 230000002146 bilateral effect Effects 0.000 claims description 3
- 230000010256 bone deposition Effects 0.000 claims description 3
- 230000008468 bone growth Effects 0.000 claims description 3
- 230000010478 bone regeneration Effects 0.000 claims description 3
- 230000024279 bone resorption Effects 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 210000004081 cilia Anatomy 0.000 claims description 3
- 230000001886 ciliary effect Effects 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims description 3
- 229960003964 deoxycholic acid Drugs 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000005538 encapsulation Methods 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- UFSKUSARDNFIRC-UHFFFAOYSA-N lumacaftor Chemical compound N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 claims description 3
- 229960000998 lumacaftor Drugs 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims description 3
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims description 3
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 108010040003 polyglutamine Proteins 0.000 claims description 3
- 229920000155 polyglutamine Polymers 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 230000020978 protein processing Effects 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 3
- 201000009890 sinusitis Diseases 0.000 claims description 3
- 239000000779 smoke Substances 0.000 claims description 3
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 229950005823 tezacaftor Drugs 0.000 claims description 3
- 210000001177 vas deferen Anatomy 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims 4
- 229920003083 Kollidon® VA64 Polymers 0.000 description 35
- 229920002517 Poloxamer 338 Polymers 0.000 description 23
- 239000000843 powder Substances 0.000 description 17
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 12
- 239000003125 aqueous solvent Substances 0.000 description 12
- 229940044476 poloxamer 407 Drugs 0.000 description 11
- 229920001992 poloxamer 407 Polymers 0.000 description 11
- 238000001694 spray drying Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 8
- 235000015165 citric acid Nutrition 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 229940005405 kalydeco Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004606 Fillers/Extenders Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000001237 Raman spectrum Methods 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229940096516 dextrates Drugs 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000007908 dry granulation Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 229960002160 maltose Drugs 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 239000004377 Alitame Substances 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 239000001329 FEMA 3811 Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004384 Neotame Substances 0.000 description 2
- 229920002675 Polyoxyl Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 229960004998 acesulfame potassium Drugs 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000019409 alitame Nutrition 0.000 description 2
- 108010009985 alitame Proteins 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000012801 analytical assay Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229940072106 hydroxystearate Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000012245 magnesium oxide Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229940032007 methylethyl ketone Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 2
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 2
- 235000010434 neohesperidine DC Nutrition 0.000 description 2
- 235000019412 neotame Nutrition 0.000 description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 2
- 108010070257 neotame Proteins 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 238000009491 slugging Methods 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010922 spray-dried dispersion Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000892 thaumatin Substances 0.000 description 2
- 235000010436 thaumatin Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940074410 trehalose Drugs 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000021400 peanut butter Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutically acceptable complex formulations comprising complexes of Ivacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Ivacaftor in solution form.
Description
COMPLEXES OF IVACAFTOR AND ITS SALTS AND DERIVATIVES, PROCESS
FOR THE PREPARATION THEREOF AND PHARMACEUTICAL
COMPOSITIONS CONTAINING THEM
FIELD OF THE INVENTION
[001] The invention is directed to a stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Ivacaftor, or its salts, or derivatives thereof, which is useful in the treatment of cystic fibrosis transmembrane conductance regulator (CFTR) mediated disease. More specifically, the complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form. The invention also relates to methods of formulating and manufacturing complexes according to the invention, pharmaceutical compositions containing it, its uses and methods of treatment using the complex and its compositions.
BACKGROUND OF THE INVENTION
FOR THE PREPARATION THEREOF AND PHARMACEUTICAL
COMPOSITIONS CONTAINING THEM
FIELD OF THE INVENTION
[001] The invention is directed to a stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Ivacaftor, or its salts, or derivatives thereof, which is useful in the treatment of cystic fibrosis transmembrane conductance regulator (CFTR) mediated disease. More specifically, the complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form. The invention also relates to methods of formulating and manufacturing complexes according to the invention, pharmaceutical compositions containing it, its uses and methods of treatment using the complex and its compositions.
BACKGROUND OF THE INVENTION
[002] The active ingredient in KALYDECO tablets is Ivacaftor, which has the following chemical name: N-(2,4-di-tert-buty1-5-hydroxypheny1)-1,4-dihydro-4-oxoquinoline-3-carboxamide. Its molecular formula is C24H28N203 and its molecular weight is 392.49. Ivacaftor has the following structural formula:
H
N HN
Ivacaftor is a white to off-white powder that is practically insoluble in water (< 0.05 microgram/mL). Due to poor aqueous solubility, extensive formulation efforts were required and resulted in a spray-dried dispersion of Ivacaftor suitable for oral administration. KALYDECO
containing the spray-dried dispersion of Ivacaftor is available as a light blue capsule-shaped, film-coated tablet for oral administration containing 150 mg of Ivacaftor. Each tablet contains the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablet film coat contains carnauba wax, FD&C Blue #2, PEG 3350, polyvinyl alcohol, talc, and titanium dioxide. The printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac.
H
N HN
Ivacaftor is a white to off-white powder that is practically insoluble in water (< 0.05 microgram/mL). Due to poor aqueous solubility, extensive formulation efforts were required and resulted in a spray-dried dispersion of Ivacaftor suitable for oral administration. KALYDECO
containing the spray-dried dispersion of Ivacaftor is available as a light blue capsule-shaped, film-coated tablet for oral administration containing 150 mg of Ivacaftor. Each tablet contains the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablet film coat contains carnauba wax, FD&C Blue #2, PEG 3350, polyvinyl alcohol, talc, and titanium dioxide. The printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac.
[003] Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR
protein.
protein.
[004] After oral administration of a single 150 mg dose to healthy volunteers in a fed state, peak plasma concentrations (t) occurred at approximately 4 hours, and the mean ( SD) for AUC
and Cm ax were 10,600 (5260) ng-thr/mL and 768 (233) ng/mL, respectively.
After every 12-hour dosing, steady-state plasma concentrations of Ivacaftor were reached by days 3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.
and Cm ax were 10,600 (5260) ng-thr/mL and 768 (233) ng/mL, respectively.
After every 12-hour dosing, steady-state plasma concentrations of Ivacaftor were reached by days 3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.
[005] The exposure of Ivacaftor increased approximately 2-to 4-fold when given with food containing fat. Therefore, KALYDECO should be administered with fat-containing food.
Examples of fat-containing foods include eggs, butter, peanut butter, and cheese pizza. The median (range) tmax is approximately 4.0 (3.0; 6.0) hours in the fed state.
Examples of fat-containing foods include eggs, butter, peanut butter, and cheese pizza. The median (range) tmax is approximately 4.0 (3.0; 6.0) hours in the fed state.
[006] The mean apparent volume of distribution (Vz/F) of Ivacaftor after a single dose of 275 mg of KALYDECO in the fed state was similar for healthy subjects and patients with CF. After oral administration of 150 mg every 12 hours for 7 days to healthy volunteers in a fed state, the mean ( SD) for apparent volume of distribution was 353 (122) L.
[007] Ivacaftor is extensively metabolized in humans. In-vitro and clinical studies indicate that Ivacaftor is primarily metabolized by CYP3A. M1 and M6 are the two major metabolites of Ivacaftor in humans. M1 has approximately one-sixth the potency of Ivacaftor and is considered pharmacologically active. M6 has less than one-fiftieth the potency of Ivacaftor and is not considered pharmacologically active.
[008] Following oral administration, the majority of Ivacaftor (87.8%) is eliminated in the feces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65%
of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of Ivacaftor as unchanged parent. The apparent terminal half-life was approximately 12 hours following a single dose. The mean apparent clearance (CL/F) of Ivacaftor was similar for healthy subjects and patients with CF. The CL/F (SD) for the 150 mg dose was 17.3 (8.4) L/hr in healthy subjects.
of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of Ivacaftor as unchanged parent. The apparent terminal half-life was approximately 12 hours following a single dose. The mean apparent clearance (CL/F) of Ivacaftor was similar for healthy subjects and patients with CF. The CL/F (SD) for the 150 mg dose was 17.3 (8.4) L/hr in healthy subjects.
[009] The main pharmacokinetic problem associated with the oral delivery of Ivacaftor is a significant positive food effect which renders the current tablet formulation to be taken with a high fat meal which results in variability of exposure and does not allow the precise dosing of the compound.
[0010] In order to overcome the problems associated with prior conventional Ivacaftor formulations and available drug delivery systems, novel complex formulations of Ivacaftor or its salts or its derivatives thereof and complexation agents and pharmaceutically acceptable excipients were prepared. The novel complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
[0011] A variety of strategies have been used to attempt to overcome these issues, see for example WO/2014/118805, WO/2014/125506, WO/2015/070336, WO/2014/135096, JP2014097964, CN104725314, U520150246031, U520150182517, W02015160787, U520150246031, U520150182517, U520150246031, U520150182517, W02015073231, EP2872122, U520150024047, EP2826776, U520150010628, EP2819670, U520140255483, U520140221424, U520140163068, U57495103, U58324242, U58354427 and U58754224.
BRIEF DESCRIPTION OF THE INVENTION
1. A stable complex with improved physicochemical characteristics and enhanced biological performance comprising i. Ivacaftor, or a salt or derivatives thereof;
ii. at least one complexation agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymers of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol succinate; and iii. optionally, pharmaceutically acceptable excipients;
wherein said complex has a particle size is between 10 nm and 600 nm, and possesses one or more among the following features:
a) is instantaneously redispersible in physiological relevant media;
b) is stable in solid form and in colloid solution and/or dispersion;
c) has an apparent solubility in water is of at least 1 mg/mL;
d) has a PAMPA permeability of at least 0.4x10-6 cm/s when dispersed in distilled water, which does not decrease in time at least for 6 months;
e) exhibits no observable food effect.
2. The complex according to Point 1, wherein said complex has a particle size in the range between 10 nm and 600 nm.
3. The complex according to Point 2, wherein said complex has a particle size in the range between 10 nm and 400 nm.
4. The complex according to Point 1, wherein said complex exhibits X-ray amorphous character in the solid form.
5. The complex according to Point 1, wherein said complex possesses at least two of the properties described in a) ¨ e).
6. The complex according to Point 5, wherein said complex possesses at least three of the properties described in a) ¨ e).
7. The complex according to Point 6, wherein said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/mL, exhibits no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Ivacaftor in solution form.
8. The complex according to Point 6, wherein said complex possesses instantaneous redispersibility, has a PAMPA permeability of at least 0.4x10-6 cm/s when dispersed in water, FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 6 month, exhibits no observable food effect which deliver the opportunity of precise dosing and ease of 5 administration of the reconstituted complex Ivacaftor in solution form.
9. The complex according to Point 5, wherein said complex has an apparent solubility in water of at least 1 mg/mL and a PAMPA permeability of at least 0.5x10-6 cm/s.
10. The complex according to Point 6, wherein said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/mL, and has a PAMPA
.. permeability of at least 0.5x10-6 cm/s.
11. The complex according to Point 1, wherein said complexation agent is selected from the group consisting of copolymers of vinylpyrrolidone and vinylacetate and poloxamers.
BRIEF DESCRIPTION OF THE INVENTION
1. A stable complex with improved physicochemical characteristics and enhanced biological performance comprising i. Ivacaftor, or a salt or derivatives thereof;
ii. at least one complexation agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymers of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol succinate; and iii. optionally, pharmaceutically acceptable excipients;
wherein said complex has a particle size is between 10 nm and 600 nm, and possesses one or more among the following features:
a) is instantaneously redispersible in physiological relevant media;
b) is stable in solid form and in colloid solution and/or dispersion;
c) has an apparent solubility in water is of at least 1 mg/mL;
d) has a PAMPA permeability of at least 0.4x10-6 cm/s when dispersed in distilled water, which does not decrease in time at least for 6 months;
e) exhibits no observable food effect.
2. The complex according to Point 1, wherein said complex has a particle size in the range between 10 nm and 600 nm.
3. The complex according to Point 2, wherein said complex has a particle size in the range between 10 nm and 400 nm.
4. The complex according to Point 1, wherein said complex exhibits X-ray amorphous character in the solid form.
5. The complex according to Point 1, wherein said complex possesses at least two of the properties described in a) ¨ e).
6. The complex according to Point 5, wherein said complex possesses at least three of the properties described in a) ¨ e).
7. The complex according to Point 6, wherein said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/mL, exhibits no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Ivacaftor in solution form.
8. The complex according to Point 6, wherein said complex possesses instantaneous redispersibility, has a PAMPA permeability of at least 0.4x10-6 cm/s when dispersed in water, FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 6 month, exhibits no observable food effect which deliver the opportunity of precise dosing and ease of 5 administration of the reconstituted complex Ivacaftor in solution form.
9. The complex according to Point 5, wherein said complex has an apparent solubility in water of at least 1 mg/mL and a PAMPA permeability of at least 0.5x10-6 cm/s.
10. The complex according to Point 6, wherein said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/mL, and has a PAMPA
.. permeability of at least 0.5x10-6 cm/s.
11. The complex according to Point 1, wherein said complexation agent is selected from the group consisting of copolymers of vinylpyrrolidone and vinylacetate and poloxamers.
12. The complex according to Point 11, wherein said complexation agent is a copolymer of vinylpyrrolidone and vinylacetate.
13. The complex according to Point 1, wherein said pharmaceutically acceptable excipient is chosen from sodium deoxycolate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
14. The complex according to Point 13, wherein said pharmaceutically acceptable excipient is sodium lauryl sulfate.
15. The complex according to Point 1 comprising a) Ivacaftor;
b) as complexation agent a copolymer of vinylpyrrolidone and vinylacetate, and optionally a poloxamer;
c) as an excipient sodium lauryl sulfate;
wherein said complex is characterized by infrared (ATR) spectrum having characteristic peaks at 588 cm-', 628 cm-', 767 cm-', 842 cm-', 962 cm-', 1019 cm-', 1108 cm-', 1148 cm-', 1240 cm-', 1343 cm-', 1370 cm-', 1425 cm-', 1465 cm-', 1525 cm-', 1567 cm-', 1666 cm-' and 1732 cm'; and is characterized by Raman shifts at 552 cm-', 648 cm-', 826 cm-' ,845 cm-', 888 cm-', 932 cm-', 1026 cm-1, 1062 cm-1, 1082 cm-1, 1129 cm-1, 1140 cm-1, 1208 cm-1, 1233 cm-1, 1262 cm-1, 1284 cm-1, 1295 cm-1, 1361 cm-1, 1450 cm-1, 1528 cm-1, 1573 cm-1, 1618 cm-1, 1677 cm-1, 1738 cm-1, 746 cm-1, 2884 cm-1 and 2936 cm-1.
b) as complexation agent a copolymer of vinylpyrrolidone and vinylacetate, and optionally a poloxamer;
c) as an excipient sodium lauryl sulfate;
wherein said complex is characterized by infrared (ATR) spectrum having characteristic peaks at 588 cm-', 628 cm-', 767 cm-', 842 cm-', 962 cm-', 1019 cm-', 1108 cm-', 1148 cm-', 1240 cm-', 1343 cm-', 1370 cm-', 1425 cm-', 1465 cm-', 1525 cm-', 1567 cm-', 1666 cm-' and 1732 cm'; and is characterized by Raman shifts at 552 cm-', 648 cm-', 826 cm-' ,845 cm-', 888 cm-', 932 cm-', 1026 cm-1, 1062 cm-1, 1082 cm-1, 1129 cm-1, 1140 cm-1, 1208 cm-1, 1233 cm-1, 1262 cm-1, 1284 cm-1, 1295 cm-1, 1361 cm-1, 1450 cm-1, 1528 cm-1, 1573 cm-1, 1618 cm-1, 1677 cm-1, 1738 cm-1, 746 cm-1, 2884 cm-1 and 2936 cm-1.
16. A complex according to either of Point 1 or Point 14 comprising a complexing agent which is selected from the group of copolymer of vinylpyrrolidone and vinylacetate and optionally poloxamers and pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 1.0 weight `)/0 to about 95.0 weight `)/0 based on the total weight of the complex.
17. A complex according to either of Point 1 or Point 14 comprising a complexation agent which is selected from the group of copolymer of vinylpyrrolidone and vinylacetate and optionally poloxamers and pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 50 weight `)/0 to about 95.0 weight `)/0 based on the total weight of the complex.
18. The complex according to Point 1, wherein said complex has an increased dissolution rate.
19. A process for the preparation of a stable complex according to Point 1, said process comprising the step of mixing a solution of Ivacaftor, and at least one complexation agent chosen from copolymers of vinylpyrrolidone and vinylacetate and optionally poloxamers, in a pharmaceutically acceptable solvent with an aqueous solution containing at least one pharmaceutically accepted excipient selected from the group of sodium deoxycholate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
20. The process according to Point 19, wherein said process is performed in a continuous flow instrument.
21. The process according to Point 20, wherein said continuous flow instrument is a microfluidic flow instrument.
22. The process according to Point 19, wherein said pharmaceutically acceptable solvent is chosen from water, methanol, ethanol, isopropanol, n-propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, or combinations thereof.
23. The process according to Point 22, wherein said pharmaceutically acceptable solvent is tetrahydrofuran.
24. The process according to Point 19, wherein said solvents are miscible with each other and the aqueous solution comprises 0.1 to 99.9% weight of the final solution.
25. A pharmaceutical composition comprising the stable complex according to Point 1 together with a pharmaceutically acceptable carrier.
26. The pharmaceutical composition according to Point 25, wherein said composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration.
27. The pharmaceutical composition according to Point 26, wherein said composition is suitable for oral administration.
28. The pharmaceutical composition comprising the complex according to Point 27, wherein said composition comprises fast dissolving granules of the complex formulation according to Point 1.
29. The pharmaceutical composition comprising the complex according to Point 28, wherein said granules are suitable for the preparation of sachet dosage form.
30. A complex according to Point 1 for use in the treatment of CFTR mediated diseases.
31. The use according to Point 30, wherein said CFTR mediated disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C
deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Naj jar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT
deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.
deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Naj jar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT
deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.
32. A method of treatment of CFTR mediated diseases comprising administration of a therapeutically effective amount of the complex according to Point 1 or the pharmaceutical composition according to Point 25.
33. A stable complex comprising a) 5 ¨ 40% by weight of Ivacaftor, or its salt or derivatives thereof;
b) 20 ¨ 80% by weight of a copolymer of vinylpyrrolidone and vinylacetate;
c) 5 ¨40 `)/0 by weight of sodium lauryl sulfate; and d) optionally 0 ¨ 50 `)/0 by weight of a poloxamer;
wherein said complex has a controlled particle size in the range between 10 nm and 600 nm; and wherein said complex is not obtained via a milling process, high pressure homogenization process, encapsulation process or solid dispersion processes.
b) 20 ¨ 80% by weight of a copolymer of vinylpyrrolidone and vinylacetate;
c) 5 ¨40 `)/0 by weight of sodium lauryl sulfate; and d) optionally 0 ¨ 50 `)/0 by weight of a poloxamer;
wherein said complex has a controlled particle size in the range between 10 nm and 600 nm; and wherein said complex is not obtained via a milling process, high pressure homogenization process, encapsulation process or solid dispersion processes.
34. The complex according to Point 1, wherein said complex further comprises one or more additional active agents.
35. The complex according to Point 27, wherein said additional active agent Lumacaftor, Tezacaftor or chosen from agents used for the treatment of CFTR mediated diseases.
DESCRIPTION OF THE INVENTION
DESCRIPTION OF THE INVENTION
36 PCT/IB2017/052370 [0012] Disclosed herein are stable complexes comprising as active compound Ivacaftor, or salts or derivatives thereof; and at least one complexation agent.
[0013] In an embodiment, said complex further comprises at least one pharmaceutically acceptable excipient.
[0014] We have found that only the selected combinations of complexation agents and pharmaceutically acceptable excipients disclosed in the present invention result in a stable complex formulations having improved physicochemical characteristics and enhanced biological performance.
[0015] The complexing agents themselves or together with the pharmaceutically acceptable excipients have the function to form a complex structure with an active pharmaceutical ingredient through non-covalent secondary interactions. The secondary interactions can form through electrostatic interactions such as ionic interactions, H-bonding, dipole-dipole interactions, dipole-induced dipole interactions, London dispersion forces, 7C-7C interactions, and hydrophobic interactions.
[0016] In an embodiment, said stable complex with improved physicochemical characteristics and enhanced biological performance comprising i. Ivacaftor, or a salt thereof or derivatives thereof;
ii. at least one complexation agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymers of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate; and iii. optionally, pharmaceutically acceptable excipients;
wherein said complex has a particle size is between 10 nm and 600 nm, and possesses one or more among the following features:
a) is instantaneously redispersible in physiological relevant media;
b) is stable in solid form and in colloid solution and/or dispersion;
c) has an apparent solubility in water is of at least 1 mg/mL;
d) has a PAMPA permeability of at least 0.4x10-6 cm/s when dispersed in distilled water, which does not decrease in time at least for 6 months; and 5 e) exhibits no observable food effect.
[0017] In an embodiment, said complexing agent is chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, 10 poly(maleic acid/methyl vinyl ether), (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (e.g; Soluplus), polyoxyl 15 hydroxystearate, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate.
[0018] In an embodiment, said complexation agent is chosen from copolymers of vinylpyrrolidone and vinyl acetate and poloxamers.
[0019] In an embodiment, said complexation agent is copolymer of vinylpyrrolidone and vinyl acetate.
[0020] In an embodiment, said copolymer of vinylpyrrolidone and vinyl acetate has a 60:40 weight ratio of vinylpyrrolidone:vinyl acetate monomers.
[0021] In an embodiment, said poloxamer is poloxamer 338.
[0022] In an embodiment, said poloxamer is poloxamer 407.
[0023] In an embodiment, said pharmaceutically acceptable excipient is chosen from sodium lauryl sulfate (SDS), dioctyl sodium sulfosuccinate (DSS), cetylpyridinium chloride (CPC), sodium acetate (Na0AC), sodium deoxycolate (SDC), meglumine, D-mannitol, Kollicoat-IR, citric acid, and lactose.
[0024] In an embodiment, said pharmaceutically acceptable excipient is chosen from sodium deoxycolate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
[0025] In an embodiment, said pharmaceutically acceptable excipient is sodium lauryl sulfate.
[0026] In some embodiments, the compositions may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof.
[0027] In an embodiment, said complex has a particle size between 10 nm and 600 nm.
[0028] In an embodiment said complex has a particle size in the range between 10 nm and 400 nm.
[0029] In an embodiment, said complex is instantaneously redispersible in physiological relevant media.
[0030] In an embodiment, said complex has increased dissolution rate compared to the commercially available form of Ivacaftor (KALYDEC00).
[0031] In an embodiment, said complex is stable in solid form and in colloid solution and/or dispersion.
[0032] In an embodiment, said complex has apparent solubility in water is at least 1 mg/mL.
[0033] In an embodiment, said complex exhibits X-ray amorphous character in the solid form.
[0034] In an embodiment, said complex has a PAMPA permeability of at least 0.4x10' cm/s when dispersed in distilled water, which does not decrease in time at least for 6 months.
[0035] In an embodiment, the variability of exposure of the complex is significantly reduced compared to the commercially available form (KALYDEC00).
[0036] In an embodiment, said complex has no observable food effect, which allows the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
[0013] In an embodiment, said complex further comprises at least one pharmaceutically acceptable excipient.
[0014] We have found that only the selected combinations of complexation agents and pharmaceutically acceptable excipients disclosed in the present invention result in a stable complex formulations having improved physicochemical characteristics and enhanced biological performance.
[0015] The complexing agents themselves or together with the pharmaceutically acceptable excipients have the function to form a complex structure with an active pharmaceutical ingredient through non-covalent secondary interactions. The secondary interactions can form through electrostatic interactions such as ionic interactions, H-bonding, dipole-dipole interactions, dipole-induced dipole interactions, London dispersion forces, 7C-7C interactions, and hydrophobic interactions.
[0016] In an embodiment, said stable complex with improved physicochemical characteristics and enhanced biological performance comprising i. Ivacaftor, or a salt thereof or derivatives thereof;
ii. at least one complexation agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymers of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate; and iii. optionally, pharmaceutically acceptable excipients;
wherein said complex has a particle size is between 10 nm and 600 nm, and possesses one or more among the following features:
a) is instantaneously redispersible in physiological relevant media;
b) is stable in solid form and in colloid solution and/or dispersion;
c) has an apparent solubility in water is of at least 1 mg/mL;
d) has a PAMPA permeability of at least 0.4x10-6 cm/s when dispersed in distilled water, which does not decrease in time at least for 6 months; and 5 e) exhibits no observable food effect.
[0017] In an embodiment, said complexing agent is chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, 10 poly(maleic acid/methyl vinyl ether), (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (e.g; Soluplus), polyoxyl 15 hydroxystearate, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate.
[0018] In an embodiment, said complexation agent is chosen from copolymers of vinylpyrrolidone and vinyl acetate and poloxamers.
[0019] In an embodiment, said complexation agent is copolymer of vinylpyrrolidone and vinyl acetate.
[0020] In an embodiment, said copolymer of vinylpyrrolidone and vinyl acetate has a 60:40 weight ratio of vinylpyrrolidone:vinyl acetate monomers.
[0021] In an embodiment, said poloxamer is poloxamer 338.
[0022] In an embodiment, said poloxamer is poloxamer 407.
[0023] In an embodiment, said pharmaceutically acceptable excipient is chosen from sodium lauryl sulfate (SDS), dioctyl sodium sulfosuccinate (DSS), cetylpyridinium chloride (CPC), sodium acetate (Na0AC), sodium deoxycolate (SDC), meglumine, D-mannitol, Kollicoat-IR, citric acid, and lactose.
[0024] In an embodiment, said pharmaceutically acceptable excipient is chosen from sodium deoxycolate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
[0025] In an embodiment, said pharmaceutically acceptable excipient is sodium lauryl sulfate.
[0026] In some embodiments, the compositions may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof.
[0027] In an embodiment, said complex has a particle size between 10 nm and 600 nm.
[0028] In an embodiment said complex has a particle size in the range between 10 nm and 400 nm.
[0029] In an embodiment, said complex is instantaneously redispersible in physiological relevant media.
[0030] In an embodiment, said complex has increased dissolution rate compared to the commercially available form of Ivacaftor (KALYDEC00).
[0031] In an embodiment, said complex is stable in solid form and in colloid solution and/or dispersion.
[0032] In an embodiment, said complex has apparent solubility in water is at least 1 mg/mL.
[0033] In an embodiment, said complex exhibits X-ray amorphous character in the solid form.
[0034] In an embodiment, said complex has a PAMPA permeability of at least 0.4x10' cm/s when dispersed in distilled water, which does not decrease in time at least for 6 months.
[0035] In an embodiment, the variability of exposure of the complex is significantly reduced compared to the commercially available form (KALYDEC00).
[0036] In an embodiment, said complex has no observable food effect, which allows the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
[0037] In an embodiment said complex containing copolymer of vinylpyrrolidone and vinylacetate and poloxamer and sodium lauryl sulfate or its pharmaceutical composition according to the invention characterized by the Raman spectrum shown in Figure 11 and ATR
spectrum shown in Figure 12.
spectrum shown in Figure 12.
[0038] In an embodiment, said complex is characterized by characteristic Raman shifts at 552 cm', 648 cm', 826 cm' ,845 cm', 888 cm', 932 cm', 1026 cm', 1062 cm', 1082 cm', 1129 cm', 1140 cm', 1208 cm', 1233 cm', 1262 cm', 1284 cm', 1295 cm', 1361 cm', 1450 cm', 1528 cm', 1573 cm', 1618 cm', 1677 cm', 1738 cm', 746 cm', 2884 cm-' and 2936 cm-'.
.. [0039] In an embodiment, said complex is characterized by ATR spectrum having characteristic peaks at 588 cm', 628 cm', 767 cm', 842 cm-' , 962 cm', 1019 cm', 1108 cm', 1148 cm', 1240 cm', 1343 cm', 1370 cm', 1425 cm', 1465 cm', 1525 cm', 1567 cm', 1666 cm -1 and 1732 cm-'.
[0040] In an embodiment said complex comprises a) Ivacaftor; or a combination of active compounds including Ivacaftor;
b) a complexing agent which is a copolymer of vinylpyrrolidone and vinyl acetate;
c) and optionally poloxamers as a complexing agent; and d) sodium lauryl sulfate as an excipient.
[0041] In an embodiment, said complex comprises a complexation agent chosen from copolymer of vinylpyrrolidone and vinyl acetate and poloxamer 407 or poloxamer 338 and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount comprising from about 1.0 weight `)/0 to about 95.0 weight `)/0 based on the total weight of the complex.
[0042] In an embodiment, said complex comprises a complexation agent chosen from copolymer of vinylpyrrolidone and vinyl acetate and poloxamer 407 or poloxamer 338 and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount comprising from about 50 weight `)/0 to about 95 weight `)/0 of the total weight of the complex.
[0043] In an embodiment, said complex comprises a complexation agent which is copolymer of vinylpyrrolidone and vinyl acetate and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount comprising from about 1.0 weight `)/0 to about 95.0 weight A ) based on the total weight of the complex.
[0044] In an embodiment, said complex comprises complexation agent which is a copolymer of vinylpyrrolidone and vinyl acetate and pharmaceutically acceptable excipient which is sodium lauryl sulfate in a total amount comprising from about 50 weight% to about 95 weight% of the total weight of the complex.
[0045] Further disclosed herein is a stable complex comprising i. 5 ¨ 40% by weight of Ivacaftor, or a salt or derivative thereof;
ii. 20 ¨ 80% by weight of a copolymer of vinylpyrrolidone and vinyl acetate;
iii. 5 ¨ 40 `)/0 by weight of sodium lauryl sulfate; and optionally iv. 0 ¨ 50 `)/0 by weight of a poloxamer.
[0046] Disclosed herein is a process for the preparation of a stable complex of Ivacaftor, said process comprising the step of mixing a solution of the active agent and at least one complexing agent and optionally one or more pharmaceutically acceptable excipient in a pharmaceutically acceptable solvent with an aqueous solution containing optionally at least one pharmaceutically acceptable excipient.
[0047] In an embodiment, said process comprises the step of mixing a solution of Ivacaftor, and at least one complexation agent chosen from copolymers of vinylpyrrolidone and vinylacetate and poloxamers, in a pharmaceutically acceptable solvent with an aqueous solution containing at least one pharmaceutically accepted excipient selected from the group of sodium deoxycolate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
[0048] In an embodiment said complex is obtained via a mixing process.
[0049] In an embodiment said complex is obtained via a continuous flow mixing process.
[0050] In an embodiment said process is performed in a continuous flow instrument.
[0051] In an embodiment said continuous flow instrument is a microfluidic flow instrument.
[0052] In an embodiment, said complex is not obtained via a milling process, high pressure homogenization process, encapsulation process and solid dispersion processes.
[0053] In an embodiment, said pharmaceutically acceptable solvent is chosen from water, methanol, ethanol, 1-propanol, 2-propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, methyl-ethyl ketone or combinations thereof.
[0054] In an embodiment, said pharmaceutically acceptable solvent is tetrahydrofuran.
[0055] In an embodiment, said pharmaceutically acceptable solvent and said aqueous solvent are miscible with each other.
[0056] In an embodiment, said aqueous solvent comprises 0.1 to 99.9% weight of the final solution.
[0057] In an embodiment, said aqueous solvent comprises 50 to 90% weight of the final solution.
[0058] In an embodiment, said aqueous solvent comprises 50 to 80% weight of the final solution.
[0059] In an embodiment, said aqueous solvent comprises 50 to 70% weight of the final solution.
[0060] In an embodiment, said aqueous solvent comprises 50 to 60% weight of the final solution.
[0061] In an embodiment, said aqueous solvent comprises 45 to 55% weight of the final solution.
[0062] In an embodiment, said aqueous solvent comprises 50 % weight of the final solution.
[0063] In an embodiment, said aqueous solvent comprises 35 to 45 % weight of the final solution.
[0064] In an embodiment, said aqueous solvent comprises 25 to 35 % weight of the final solution.
[0065] In an embodiment, said aqueous solvent comprises 15 to 25 % weight of the final solution.
[0066] In an embodiment, said aqueous solvent comprises 5 to 15 % weight of the final solution.
[0067] In an embodiment, a pharmaceutical composition comprising the complex together with pharmaceutically acceptable carriers.
[0068] In an embodiment, said composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracistemal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration.
[0069] In an embodiment, said compositions are suitable for oral administration.
5 [0070] In an embodiment, said composition comprises fast dissolving granules of the complex Ivacaftor formulation.
[0071] In an embodiment, said granules are suitable for the preparation of sachet dosage form.
[0072] In an embodiment, said complexes are for use in the manufacture of a medicament for the treatment of CFTR mediated diseases.
10 [0073] In an embodiment, said complexes are used for the treatment of CFTR mediated diseases.
[0074] CFTR mediated disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary 15 disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Naj jar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT
deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.
[0075] In an embodiment, a method of treatment of CFTR mediated diseases comprises administration of a therapeutically effective amount of complexes or pharmaceutical compositions as described herein.
[0076] In an embodiment, a method for reducing the therapeutically effective dosage of Ivacaftor compared to commercially available KALYDECOO comprises oral administration of a pharmaceutical composition as described herein.
[0077] In an embodiment, said complexes further comprise one or more additional active agents.
[0078] In an embodiment, said additional active agent is Lumacaftor, Tezacaftor or chosen from agents used for the treatment of CFTR mediated diseases.
[0079] In an embodiment said complex comprises Ivacaftor; or a combination of active compounds including Ivacaftor; a complexing agent chosen from copolymers of vinylpyrrolidone and vinyl acetate and sodium lauryl sulfate as an excipient; said complex characterized in that they possess at least one of the following properties:
a) is instantaneously redispersable in physiological relevant media;
b) is stable in solid form and in colloid solution and/or dispersion;
c) has an apparent solubility in water of at least 1 mg/mL;
d) has a PAMPA permeability of at least 0.4x10' cm/s when dispersed in FaSSIF
or FeSSIF
biorelevant media, which does not decrease in time at least for 6 month;
e) exhibits no observable food effect.
[0080] In an embodiment, said complex possesses at least two of the properties described in a) ¨
e).
[0081] In an embodiment, said complex possesses at least three of the properties described in a) ¨ e).
[0082] The novel complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
[0083] The expression Ivacaftor is generally used for Ivacaftor, or its salts or its derivatives.
[0084] In an embodiment, said complexation agent is chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyoxyl 15 hydroxystearate, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate.
[0085] In an embodiment, said complexation agents are copolymer of vinylpyrrolidone and vinyl acetate and poloxamer and said pharmaceutically acceptable excipient is sodium lauryl sulfate, and a) is characterized by infrared (ATR) spectrum having characteristic absorption peaks at 588 cm-', 628 cm-', 767 cm-', 842 cm-', 962 cm-', 1019 cm-', 1108 cm-', 1148 cm-', 1240 cm-', 1343 cm-', 1370 cm-', 1425 cm-', 1465 cm-', 1525 cm-', 1567 cm-', 1666 cm-' and 1732 cm';
and b) has characteristic Raman shifts at 552 cm-', 648 cm-', 826 cm-' ,845 cm-', 888 cm-', 932 cm-', 1026 cm-', 1062 cm-', 1082 cm-', 1129 cm-', 1140 cm-', 1208 cm-', 1233 cm-', 1262 cm-', 1284 cm 1, 1295 cm-', 1361 cm-', 1450 cm-', 1528 cm-', 1573 cm-', 1618 cm-', 1677 cm-', 1738 cm-', 746 cm 1, 2884 cm-' and 2936 cm-'.
[0086] In some embodiments, the compositions may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof. In some embodiments, active agents may include agents useful for the treatment of CFTR mediated diseases.
[0087] Another aspect of the invention is the complex formulations of the Ivacaftor with complexation agents and pharmaceutically acceptable excipients in which the complexation agents and pharmaceutically acceptable excipients preferably are associated or interacted with the Ivacaftor, such as the results of a mixing process or a continuous flow mixing process. In some embodiment, the structure of the complex Ivacaftor formulations is different from the core-shell type milled particle, precipitated encapsulated particles, micelles and solid dispersions.
[0088] The pharmaceutical composition of the invention can be formulated: (a) for administration selected from the group consisting of oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, and topical administration; (b) into a dosage form selected from the group consisting of liquid dispersions, gels, aerosols, ointments, creams, lyophilized formulations, tablets, capsules; (c) into a dosage form selected from the group consisting of controlled release formulations, fast melt formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations;
or (d) any combination of (a), (b), and (c).
[0089] The compositions can be formulated by adding different types of pharmaceutically acceptable excipients for oral administration in solid, liquid, local (powders, ointments or drops), or topical administration, and the like.
[0090] In an embodiment, the dosage form of the invention is a solid dosage form, although any pharmaceutically acceptable dosage form can be utilized.
[0091] Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders (sachet), and granules. In such solid dosage forms, the complex formula of Ivacaftor is admixed with at least one of the following: one or more inert excipients (or carriers):
(a) fillers or extenders, such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, erythritol, fructose, isomalt, lactitol, maltitol, maltose, maltodextrin, trehalose, xylitol, starches, microcrystalline cellulose, dicalcium phosphate, calcium carbonate, magnesium .. carbonate, magnesium oxide; (b) sweetening, flavoring, aromatizing and perfuming agents such as saccharin, saccharin sodium, acesulfame potassium, alitame, aspartame, glycine, inulin, neohesperidin dihydrochalcone, neotame, sodium cyclamate, sucralose, tagatose, thaumatin, citric acid, adipic acid, fumaric acid, leucine, malic acid, menthol, propionic acid, tartaric acid; (c) binders, such as cellulose derivatives, acrylic acid derivatives, alginates, gelatin, polyvinylpyrrolidone, starch derivatives, dextrose, dextrates, dextrin, maltose, maltodextrin; (d) disintegrating agents, such as crospovidon, effervescent compositions, croscarmellose sodium and other cellulose derivatives, sodium starch glycolate and other starch derivatives, alginic acid, certain complex silicates and sodium carbonate; (e) solution retarders, such as acrylates, cellulose derivatives, paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as polysorbates, cetyl alcohol and glycerol monostearate;
(h) lubricants such as talc, stearic acid and its derivatives, solid polyethylene glycols, sodium lauryl sulfate, glyceryl behenate, medium-chain triglycerides or mixtures thereof. For capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
[0092] In an embodiment, the dosage form of the invention is a liquid dispersible granules in a sachet form.
[0093] In an embodiment, said liquid dispersible granules comprise the complex formulation of Ivacaftor of the present invention together with pharmaceutically acceptable excipients selected from the group of fillers or extenders, such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, erythritol, fructose, isomalt, lactitol, maltitol, maltose, maltodextrin, trehalose, xylitol, starches, microcrystalline cellulose, dicalcium phosphate, calcium carbonate, magnesium carbonate, magnesium oxide.
[0094] In an embodiment, said liquid dispersible granules comprise the complex formulation of Ivacaftor of the present invention together with pharmaceutically acceptable excipients selected from the group of sweetening, flavoring, aromatizing and perfuming agents such as saccharin, saccharin sodium, acesulfame potassium, alitame, aspartame, glycine, inulin, neohesperidin dihydrochalcone, neotame, sodium cyclamate, sucralose, tagatose, thaumatin, citric acid, adipic acid, fumaric acid, leucine, malic acid, menthol, propionic acid, tartaric acid.
[0095] Further disclosed herein is a liquid dispersible granules comprising a. 25 ¨95 `)/0 stable complex formulation of Ivacaftor of the present invention;
b. 5 ¨75 A fillers or extenders;
c. 0.5 ¨25 A binders;
d. 0.1 ¨5 `)/0 sweetening, flavoring, aromatizing and perfuming agents;
wherein said liquid dispersible granules disperses within 3 min in liquid; and wherein said liquid dispersible granules obtained by wet or dry processes.
[0096] In an embodiment, said dispersion time is between 0.1 min and 10 min.
[0097] In an embodiment, said dispersion time is between 0.1 min and 5 min.
[0098] In an embodiment, said dispersion time is between 0.1 min and 3 min.
[0099] In an embodiment, said dispersion time is between 0.1 min and 1 min.
[00100]In an embodiment, Hausner-ratio of the said liquid dispersible granules of complex Ivacaftor formulations is less than 1.25 more preferably 1.00-1.18 5 [00101]In an embodiment, Hausner-ratio of the said liquid dispersible granules of complex Ivacaftor formulations is between 1.00 and 1.18.
[00102]In an embodiment, the particle size (D(90)) of said solid aggregates of complex Ivacaftor formulations is less than 2000 micrometers.
[00103]In an embodiment, 60-99 Yo of the said solid aggregates of complex Ivacaftor 10 formulations are in the size range of 160-1200 micrometers [00104]In an embodiment, said liquid is water, saliva, other physiologically or biologically acceptable fluid.
[00105]In an embodiment, the dosage form is chosen from a tablet and a capsule.
[00106] Advantages of the complex Ivacaftor formulations of the invention include, but are not 15 limited to (1) physical and chemical stability, (2) instantaneous redispersibility, (3) stability in colloid solution or dispersion in the therapeutic time window, (4) increased apparent solubility and permeability compared to the conventional Ivacaftor formulation, (5) no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex formulation in solution form, (6) good processability.
20 [00107] Beneficial features of the present invention are as follows: the good/instantaneous redispersibility of solid complex formulations of Ivacaftor in water, biologically relevant media, e.g. physiological saline solution, pH=2.5 HC1 solution, FessiF and FassiF
media and gastro intestinal fluids and adequate stability in colloid solutions and/or dispersion in the therapeutic time window.
[00108] In an embodiment, the complex Ivacaftor formulations of the present invention has increased apparent solubility and permeability. In some embodiments, the apparent solubility and permeability of the complex Ivacaftor formulae is at least 1 mg/mL and 0.5x10-6 cm/s, respectively.
[00109] In an embodiment, said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/mL, and has a PAMPA permeability of at least 0.5x10' cm/s.
[00110] The complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted solid.
[00111] The complexes of the present invention possess instantaneous redispersibility, has a PAMPA permeability of at least 0.4x10-6 cm/s when dispersed in water, FaSSIF
or FeSSIF
biorelevant media, which does not decrease in time at least for 6 month, exhibits no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Ivacaftor in solution form.
BRIEF DESCRIPTION OF THE DRAWINGS
[00112]The accompanying figures, which are incorporated and form part of the specification, merely illustrate certain embodiments of the present invention and should not be construed as limiting the invention. They are meant to serve to explain specific modes of the present invention to those skilled in the art.
Figure 1. Redispersibility of complex Ivacaftor compositions in ultrapurified water.
Figure 2. Redispersibility and PAMPA permeability of complex Ivacaftor compositions.
Figure 3. Redispersibility and PAMPA permeability of complex Ivacaftor compositions containing vinylpyrrolidone and vinylacetate copolymer (Kollidon VA 64) and poloxamer in different ratios.
Figure 4. Redispersibility and PAMPA permeability of complex Ivacaftor compositions containing vinylpyrrolidone and vinylacetate copolymer (Kollidon VA 64) itself and in combination with different poloxamers.
Figure 5. Physical appearance and stability of the produced complex Ivacaftor formula.
Figure 6. Physical appearance and stability of the produced complex Ivacaftor formula during the flow optimization.
Figure 7. Ivacaftor dissolution from granulated complex Ivacaftor formulation.
Figure 8. PAMPA permeability of complex Ivacaftor formulation in biorelevant media.
Figure 9. PAMPA permeability of complex Ivacaftor formulations stored at different condition and measured at different time points.
Figure 10. SEM photo of complex Ivacaftor formulation.
Figure 11. Raman spectra of crystalline Ivacaftor (A), freeze-dried Ivacaftor (B), complex Ivacaftor formulation (C), Placebo sample (prepared in the absence of Ivacaftor) (D), copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA64) (E), sodium lauryl sulfate (F) and poloxamer 338 (Pluronic F108) (G).
Figure 12. ATR spectra of crystalline Ivacaftor (A), amorphous Ivacaftor (B), complex Ivacaftor formulation (C), placebo (prepared in the lack of Ivacaftor) (D), copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA64) (E), sodium lauryl sulfate (F) and poloxamer 338 (Pluronic F108) (G).
Figure 13. XRD diffractogram of amorphous Ivacaftor and complex Ivacaftor.
Figure 14. PAMPA permeability of crystalline Ivacaftor, solid dispersion of Ivacaftor, complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA
64), poloxamer 338 (Pluronic F108)and sodium lauryl sulfate, complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 407 (Lutrol F127) and sodium lauryl sulfate and complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64) and sodium lauryl sulfate.
Figure 15. Comparative apparent solubility data of different Ivacaftor formulations.
Figure 16. Comparative dissolution tests of solid dispersion of Ivacaftor and complex Ivacaftor formulation.
Figure 17. Plasma concentrations of Ivacaftor following the oral administration of novel complex in the fasted and in the fed state to beagle dogs at 3 mg/kg dose (N=4).
Figure 18. Pharmacokinetic parameters following the oral administration of novel complex in the fasted and in the fed state to beagle dogs at 3 mg/kg dose (N=4).
EXAMPLES
[00113] Specific embodiments of the present invention will further be demonstrated by the following examples. It should be understood that these examples are disclosed only by way of .. illustration and should not be construed as limiting the scope of the present invention.
Selection of complex Ivacaftor formulations with improved material properties [00114] Several complexation agents and pharmaceutically acceptable excipients and their combinations were tested in order to select the formulations having instantaneous redispersibility as shown in Figure 1.
[00115]Examples that displayed an acceptable level of redispersibility was selected for further analysis.
[00116]PAMPA permeability of the selected formulations was measured in order to select the complex Ivacaftor formulation having the best in-vitro performance (Figure 2).
PAMPA
permeability measurements were performed as described by M. Kansi et al.
(Journal of medicinal .. chemistry, 41, (1998) pp 1007) with modifications based on S. Bendels et al (Pharmaceutical research, 23 (2006) pp 2525). Permeability was measured in a 96-well plate assay across an artificial membrane composed of dodecane with 20% soy lecithin supported by a PVDF
membrane (Millipore, USA). The receiver compartment was phosphate buffered saline (pH 7.0) supplemented with 1% sodium dodecyl sulfate. The assay was performed at room temperature;
incubation time was 4 hours in ultrapurified water, FaSSIF and FeSSIF, respectively. The concentration in the receiver compartment was determined by UV-VIS
spectrophotometry (VWR UV-3100PC Scanning Spectrophotometer).
[00117]Copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) itself and in combination with poloxamer 338 (Pluronic F108) or poloxamer 407 (Lutrol F127) were selected .. as complexation agents and sodium lauryl sulfate was selected as pharmaceutically acceptable excipient in order to prepare complex Ivacaftor formulations having improved material characteristics.
[00118]The ratio of the selected complexation agents and pharmaceutically acceptable excipients was optimized. Solid complexes of Ivacaftor were prepared by using different ratios of .. complexation agents and pharmaceutically acceptable excipients (Figure 3 and Figure 4).
Production of complex Ivacaftor formulations [00119] In order to select the best complex formulation, a solution mixture of Ivacaftor complex formula was prepared. 100 mL Solution 1 was prepared by dissolving 100 mg Ivacaftor and 300 mg copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 200 mg poloxamer 338 (Pluronic F108) in 100 mL tetrahydrofurane. The prepared Solution 1 was mixed with Solution 2 containing 25-100 mg sodium lauryl sulfate in 100 mL in order to produce complex Ivacaftor formulation. The appearance and stability of produced colloid solution were monitored. Based on the physical appearance and stability of the produced complex Ivacaftor formula in colloid solution, the best composition was selected for analytical investigations and further work (Figure .. 4 and Figure 5).
[00120] In order to select a complex formulation without poloxamer, a solution mixture of Ivacaftor complex formula was prepared. 100 mL Solution 1 was prepared by dissolving 100 mg Ivacaftor and 600 mg copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) in 100 mL tetrahydrofurane. The prepared Solution 1 was mixed with Solution 2 containing 300 mg sodium lauryl sulfate in 100 mL in order to produce complex Ivacaftor formulation. The composition was selected for analytical investigations and further work.
In order to select a complex formulation with poloxamer previously not mentioned, a solution mixture of Ivacaftor complex formula was prepared. 100 mL Solution 1 was prepared by dissolving 100 mg Ivacaftor and 300 mg copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 60-200 mg poloxamer 407 (Lutrol F127) in 100 mL
tetrahydrofurane. The prepared Solution 1 was mixed with Solution 2 containing 60-100 mg sodium lauryl sulfate in 100 mL in order to produce complex Ivacaftor formulation.
Continuous flow production of complex Ivacaftor formulations [00121]In order to make the production process industrially feasible, flow production was needed and process intensification was performed by increasing the concentrations of the starting solutions. For the experiments, 1:1 Solvent 1: Solvent 2 ratio was used. A
colloid solution of complex Ivacaftor formulation of the present invention was prepared by mixing process.
Solution 1 containing 500 mg Ivacaftor and 1500 mg copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 1000 mg poloxamer 338 (Pluronic F108) in 100 mL
tetrahydrofuran was mixed with aqueous Solution 2 containing 500 mg sodium lauryl sulfate in 100 mL ultrapurified water in different flow rates. The colloid solution of the complex Ivacaftor formulation was produced at atmospheric pressure and 20-50 C temperature. The appearance and stability of the produced colloid solution were monitored. Based on the physical appearance and stability of the produced complex Ivacaftor formulation in colloid solution, the best composition was selected for spray-drying experiments. Figure 6 summarizes the results.
[00122]The solidification of the colloid solution was performed by spray-drying technique. 5 5 mg/mL Ivacaftor, 15 mg/mL copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 10 mg/mL poloxamer 338 (Pluronic F108) in tetrahydrofurane and 5 mg/mL
sodium lauryl sulfate in water were chosen for starting concentrations. The ratio of the solutions was found to be optimal at 1:1 ratio. The colloid solution of the complex Ivacaftor formulation prepared by the optimal parameter sets was spray-dried (Yamato DL-410 / GAS410) in order to obtain solid 10 powder. The spray-drying process was optimized. The optimal production parameters were found to be Tõ,=95 C, V.r=0.8 m3/min, M18 mL/min, p=1 bar, Tout= 57-60 C.
[00123] The solidification of the colloid solution was performed by spray-drying technique. 5 mg/mL Ivacaftor, 30 mg/mL copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) in tetrahydrofurane and 15 mg/mL sodium lauryl sulfate in water were chosen for starting 15 concentrations. The ratio of the solutions was found to be optimal at 1:1 ratio. The colloid solution of the complex Ivacaftor formulation prepared by the optimal parameter sets was spray-dried (Yamato DL-410 / GAS410) in order to obtain solid powder. The spray-drying process was optimized. The optimal production parameters were found to be Tõ=95 C, V.r=0.8 m3/min, 1\418 mL/min, p=1 bar, Tout= 55-58 C.
20 [00124]The solidification of the colloid solution was performed by spray-drying technique. 5 mg/mL Ivacaftor, 15 mg/mL copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 10 mg/mL poloxamer 407 (Lutrol F127) in tetrahydrofurane and 5 mg/mL
sodium lauryl sulfate in water were chosen for starting concentrations. The ratio of the solutions was found to be optimal at 1:1 ratio. The colloid solution of the complex Ivacaftor formulation prepared by 25 the optimal parameter sets was spray-dried (Yamato DL-410 / GAS410) in order to obtain solid powder. The spray-drying process was optimized. The optimal production parameters were found to be Tõ,=95 C, V.r=0.8 m3/min, M18 mL/min, p=1 bar, Tout= 57-60 C.
[00125] The solidification of the colloid solution was performed by spray-drying technique. 5 mg/mL Ivacaftor, 15 mg/mL copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 3 mg/mL poloxamer 407 (Lutrol F127) in tetrahydrofurane and 3 mg/mL sodium lauryl sulfate in water were chosen for starting concentrations. The ratio of the solutions was found to be optimal at 1:1 ratio. The colloid solution of the complex Ivacaftor formulation prepared by the optimal parameter sets was spray-dried (Yamato DL-410 / GAS410) in order to obtain solid powder. The spray-drying process was optimized. The optimal production parameters were found to be Ttet=95 C, Va,r=0.85 m3/min, M18 mL/min, p=1 bar, Tout= 61 C.
Preparation of liquid dispersible granules comprising complex Ivacaftor formulation [00126]Liquid dispersible granules comprising the complex Ivacaftor formulations of the present invention can be obtained by wet or dry granulation processes.
[00127]Dry granulation process includes, but not limited to the slugging or roll compaction of the powder formulation of complex Ivacaftor into compacts and breaking of the compacts into granules with appropriate mesh size. The obtained granules can be blended with pharmaceutically acceptable excipients.
[00128]Dry granulation technique can be also applied on the powder blend of complex Ivacaftor formulations. Powder blend consists of the powder formulation of complex Ivacaftor and pharmaceutically acceptable excipients and prepared by blending of the powders. Slugging or roll compaction are used to manufacture compacts from the powder blend. Then the compacts are broken into granules with appropriate mesh size.
[00129]Wet granulation process covers the moisturizing of the powder formulations of complex Ivacaftor (direct granulation) or moisturizing the pharmaceutically acceptable excipients with aqueous solution of pharmaceutically acceptable binders and blending it with the powder formulations of complex Ivacaftor (indirect granulation). The particle size of the granules can be controlled by physical impact before and after the drying step.
[00130]Liquid dispersible granules of complex Ivacaftor formulation of the present invention were prepared by compacting appropriate amount of complex Ivacaftor powder blend using 0.5 ton load. The powder blend comprised of the solid formulation of the complex of Ivacaftor and pharmaceutically acceptable excipients selected from the group of sweetening, flavouring, aromatizing and perfuming agents. The height of the compact was found to be optimal between 0.8-1.0 mm. The compacts were broken up by physical impact to form granulates.
The particle size of the granules was controlled by sieving with appropriate mesh size to achieve 160-800 micrometres particle size.
Comparative solubility tests [00131] The apparent solubility of the granulated complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium-lauryl-sulfate was measured by UV-VIS spectroscopy at room temperature. The solid complex Ivacaftor formulations were dispersed in ultrapurified water in 1-10 mg/mL Ivacaftor equivalent concentration range. The resulting solutions were filtered by 100 nm disposable syringe filter. The Ivacaftor content in the filtrate was measured by UV-Vis spectrophotometry and the apparent solubility was calculated. The filtrate may contain Ivacaftor complex particles which could not be filtrated out using 100 nm pore size filter.
[00132]The apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64) and sodium lauryl sulfate and poloxamer 338 of the present invention was 0.991; 2.356; 4.924 and 9.463 mg/mL, when 1; 2.5;
5; and 10 mg/mL Ivacaftor equivalent formulations were dispersed in ultrapurified water, respectively.
[00133]Apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64) and sodium lauryl sulfate and poloxamer 338 was 9.463 mg/mL.
[00134] The apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), and sodium lauryl sulfate was measured by UV-VIS spectroscopy at room temperature. The solid complex Ivacaftor formulations were dispersed in ultrapurified water in 1 mg/mL Ivacaftor equivalent concentration range. The resulting solutions were filtered by 100 nm disposable syringe filter. The Ivacaftor content in the filtrate was measured by UV-Vis spectrophotometry and the apparent solubility was calculated.
The filtrate may contain Ivacaftor complex particles which could not be filtrated out using 100 nm pore size filter.
[00135]The apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64) and sodium lauryl sulfate was 0.936 mg/mL
when 1 mg/mL Ivacator equivalent formulation was dispersed in ultrapurified water.
[00136]Apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64) and sodium lauryl sulfate was 0.936 mg/mL.
[00137] The apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 407 (Lutrol F127) and sodium-lauryl-sulfate was measured by UV-VIS spectroscopy at room temperature.
The solid complex Ivacaftor formulations were dispersed in ultrapurified water in 1 mg/mL Ivacaftor equivalent concentration range. The resulting solutions were filtered by 100 nm disposable syringe filter. The Ivacaftor content in the filtrate was measured by UV-Vis spectrophotometry and the apparent solubility was calculated. The filtrate may contain Ivacaftor complex particles which could not be filtrated out using 100 nm pore size filter.
[00138]The apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 407 and sodium lauryl sulfate was 0.944 mg/mL when 1 mg/mL Ivacator equivalent formulation was dispersed in ultrapurified water.
[00139]Apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 407 and sodium lauryl sulfate was 0.944 mg/mL.
Dissolution test [00140]Ivacaftor dissolution was measured from the dry granulated formulation of the complex Ivacaftor containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate. The dissolution test was performed by dispersing the granulated complex Ivacaftor formulation in purified water at 1 mg/mL
concentrations. The dissolved amount was measured with UV-VIS
spectrophotometry after filtration with 0.1 1,1m pore size filter at different time points.
Dissolution of Ivacaftor from the granulated complex formulation was instantaneous, within 10 minutes 95 A of the Ivacaftor dissolved from the granulated complex Ivacaftor formulation (Figure 7).
Comparative in-vitro PAMPA assays [00141]PAMPA permeabilities of complex Ivacaftor formulations were measured in water, FaSSIF and FeSSIF media and were found to be above 0.4x10' cm/s in all tested media (Figure 8).
Stability of the solid formulation of complex Ivacaftor [00142] PAMPA permeability of the solid complex Ivacaftor formulations was used to monitor the physical stability of the formulation. PAMPA permeability was measured after storage of the complex Ivacaftor formulation at different conditions. 6 month storage at RT or 40 C relative humidity showed no significant decrease in the measured PAMPA
permeability under any of the conditions tested (Figure 9).
Structural analysis [00143]Morphology of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate was investigated using FEI Quanta 3D scanning electron microscope. Complex Ivacaftor formulation of the present invention comprises spherical particles with particle size less than 50 nm (Figure 10).
[00144] Structural analysis was performed by using Vertex 70 FT-IR with ATR
and HORTB_A.
jobinYvon LabRAN HR UV-NTS-NM instruments.
[00145]Complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate or its pharmaceutical composition according to the invention is characterized by the Raman spectrum shown in Figure 11 and ATR spectrum shown in Figure 12.
[00146]Complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate or its pharmaceutical composition according to the invention is characterized by Raman shifts at 552 cm-1, 648 cm-1, 826 cm-1 ,845 cm-1, 888 cm-1, 932 cm-1, 1026 cm-1, 1062 cm-1, 1082 cm-1, 1129 cm-1, 1140 cm-1, 1208 cm-1, 1233 cm-1, 1262 cm-1, 1284 cm-1, 1295 cm-1, 1361 cm-1, 1450 cm-1, 1528 cm-1, 1573 cm-1, 1618 cm-1, 1677 cm-1, 1738 cm-1, 746 cm-1, 2884 cm-1 and 2936 cm-1.
[00147]Complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate or its pharmaceutical composition according to the invention is characterized by Raman shifts at 1082 cm-1, 1233 cm-1, 1284 cm-1, 1361 cm-1, 1528 cm-1, 1618 cm-1 and 1738 cm-1.
[00148]Complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate or its pharmaceutical composition is characterized by infrared (ATR) spectrum having characteristic peaks at 588 cm-1, 628 cm-1, 767 cm-1, 842 cm', 962 cm-1, 1019 cm-1, 1108 cm-1, 1148 cm-1, 1240 cm-1, 1343 cm-1, 1370 cm-1, 1425 cm-1, 1465 cm-1, 1525 cm-1, 1567 cm-1, 1666 cm-1 and 1732 cm-1.
[00149] Complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate or its pharmaceutical composition is characterized by ATR spectrum having characteristic peaks at 628 cm', 767 cm', 1108 cm', 1370 cm', 1465 cm-' and 1666 cm'.
5 [00150]The structure of the complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate was investigated by powder X-ray diffraction (XRD) analysis (Philips PW1050/1870 RTG powder-diffractometer). The measurements showed that the Ivacaftor in the complex formulations was XRD amorphous (Figure 13). Characteristic reflections on the diffractograms 10 of complex Ivacaftor formulation at 43 and 44 2Theta could be attributed to sample holder.
Comparative formulation study [00151]Ivacaftor is marketed in its solid dispersion form under the trade name of 15 KALYDECOO. Manufacturing of solid dispersion of Ivacaftor is described in US 20140221424 Al patent application. Using the manufacturing method described in the patent application, solid dispersion of Ivacaftor was prepared for comparative analytical assays. A
solvent system of methyl ethyl ketone (MEK) and water in the ratio of 90 wt `)/0 MEK : 10 wt `)/0 water was heated to 20-30 C in a reaction vessel equipped with a magnetic stirrer and thermal circuit. Into this 20 solvent system, hypromellose acetate succinate polymer (HPMCAS), sodium lauryl sulfate and Ivacaftor were added in the ratio of 19.5 wt `)/0 hypromellose acetate succinate : 0.5 wt `)/0 SLS:80 wt `)/0 Ivacaftor. The resulting mixture was solid formulated by spray-drying method.
[00152]Comparative analytical assays were used to investigate the physicochemical properties of the formulation prepared by solid dispersion technology and continuous flow mixing of the 25 present invention.
[00153]PAMPA permeability of the solid dispersion could not be detected in water and FaSSIF
media, while it was 70 A of the permeability of the complex Ivacaftor formulation of the present invention in FeSSIF (Figure 14).
[00154]Comparative apparent solubility measurements showed that the apparent solubility of 30 complex Ivacaftor formulation was at least 0.9 mg/mL, while apparent solubility of crystalline Ivacaftor, Ivacaftor in physical mixture, amorphous Ivacaftor in aqueous sodium lauryl sulfate solution and solid dispersion was below 0.1 mg/mL (Figure 15).
[00155]Comparative dissolution tests performed in water showed that the dissolution of Ivacaftor from the granulated complex formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate was instantaneous, within 10 minutes 90 A of the Ivacaftor dissolved from the granulated complex Ivacaftor formulation, while 0 A Ivacaftor dissolved from the solid dispersion in 60 minutes (Figure 16).
In-vivo pharmacokinetics /n-vivo PK test in large animals [00156]A beagle dog study using the granulated complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate of the present invention at a dose of 3 mg/kg was performed in the fasted and fed state. The granulated complex formulation was administered to the animals orally as reconstituted dispersion. Food effect was only 1.1-fold (food effect in humans is 2-4-fold higher in the fed state, that is why the drug has to be taken after a high fat meal). Exposure was 1.25-times higher than the reference exposure. Cm ax was somewhat lower for the complex Ivacaftor formulation, however, for the more important parameter, C24,, the complex Ivacaftor was 1.4-times higher (Figure 17 and Figure 18).
[00157]From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
.. [0039] In an embodiment, said complex is characterized by ATR spectrum having characteristic peaks at 588 cm', 628 cm', 767 cm', 842 cm-' , 962 cm', 1019 cm', 1108 cm', 1148 cm', 1240 cm', 1343 cm', 1370 cm', 1425 cm', 1465 cm', 1525 cm', 1567 cm', 1666 cm -1 and 1732 cm-'.
[0040] In an embodiment said complex comprises a) Ivacaftor; or a combination of active compounds including Ivacaftor;
b) a complexing agent which is a copolymer of vinylpyrrolidone and vinyl acetate;
c) and optionally poloxamers as a complexing agent; and d) sodium lauryl sulfate as an excipient.
[0041] In an embodiment, said complex comprises a complexation agent chosen from copolymer of vinylpyrrolidone and vinyl acetate and poloxamer 407 or poloxamer 338 and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount comprising from about 1.0 weight `)/0 to about 95.0 weight `)/0 based on the total weight of the complex.
[0042] In an embodiment, said complex comprises a complexation agent chosen from copolymer of vinylpyrrolidone and vinyl acetate and poloxamer 407 or poloxamer 338 and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount comprising from about 50 weight `)/0 to about 95 weight `)/0 of the total weight of the complex.
[0043] In an embodiment, said complex comprises a complexation agent which is copolymer of vinylpyrrolidone and vinyl acetate and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount comprising from about 1.0 weight `)/0 to about 95.0 weight A ) based on the total weight of the complex.
[0044] In an embodiment, said complex comprises complexation agent which is a copolymer of vinylpyrrolidone and vinyl acetate and pharmaceutically acceptable excipient which is sodium lauryl sulfate in a total amount comprising from about 50 weight% to about 95 weight% of the total weight of the complex.
[0045] Further disclosed herein is a stable complex comprising i. 5 ¨ 40% by weight of Ivacaftor, or a salt or derivative thereof;
ii. 20 ¨ 80% by weight of a copolymer of vinylpyrrolidone and vinyl acetate;
iii. 5 ¨ 40 `)/0 by weight of sodium lauryl sulfate; and optionally iv. 0 ¨ 50 `)/0 by weight of a poloxamer.
[0046] Disclosed herein is a process for the preparation of a stable complex of Ivacaftor, said process comprising the step of mixing a solution of the active agent and at least one complexing agent and optionally one or more pharmaceutically acceptable excipient in a pharmaceutically acceptable solvent with an aqueous solution containing optionally at least one pharmaceutically acceptable excipient.
[0047] In an embodiment, said process comprises the step of mixing a solution of Ivacaftor, and at least one complexation agent chosen from copolymers of vinylpyrrolidone and vinylacetate and poloxamers, in a pharmaceutically acceptable solvent with an aqueous solution containing at least one pharmaceutically accepted excipient selected from the group of sodium deoxycolate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
[0048] In an embodiment said complex is obtained via a mixing process.
[0049] In an embodiment said complex is obtained via a continuous flow mixing process.
[0050] In an embodiment said process is performed in a continuous flow instrument.
[0051] In an embodiment said continuous flow instrument is a microfluidic flow instrument.
[0052] In an embodiment, said complex is not obtained via a milling process, high pressure homogenization process, encapsulation process and solid dispersion processes.
[0053] In an embodiment, said pharmaceutically acceptable solvent is chosen from water, methanol, ethanol, 1-propanol, 2-propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, methyl-ethyl ketone or combinations thereof.
[0054] In an embodiment, said pharmaceutically acceptable solvent is tetrahydrofuran.
[0055] In an embodiment, said pharmaceutically acceptable solvent and said aqueous solvent are miscible with each other.
[0056] In an embodiment, said aqueous solvent comprises 0.1 to 99.9% weight of the final solution.
[0057] In an embodiment, said aqueous solvent comprises 50 to 90% weight of the final solution.
[0058] In an embodiment, said aqueous solvent comprises 50 to 80% weight of the final solution.
[0059] In an embodiment, said aqueous solvent comprises 50 to 70% weight of the final solution.
[0060] In an embodiment, said aqueous solvent comprises 50 to 60% weight of the final solution.
[0061] In an embodiment, said aqueous solvent comprises 45 to 55% weight of the final solution.
[0062] In an embodiment, said aqueous solvent comprises 50 % weight of the final solution.
[0063] In an embodiment, said aqueous solvent comprises 35 to 45 % weight of the final solution.
[0064] In an embodiment, said aqueous solvent comprises 25 to 35 % weight of the final solution.
[0065] In an embodiment, said aqueous solvent comprises 15 to 25 % weight of the final solution.
[0066] In an embodiment, said aqueous solvent comprises 5 to 15 % weight of the final solution.
[0067] In an embodiment, a pharmaceutical composition comprising the complex together with pharmaceutically acceptable carriers.
[0068] In an embodiment, said composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracistemal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration.
[0069] In an embodiment, said compositions are suitable for oral administration.
5 [0070] In an embodiment, said composition comprises fast dissolving granules of the complex Ivacaftor formulation.
[0071] In an embodiment, said granules are suitable for the preparation of sachet dosage form.
[0072] In an embodiment, said complexes are for use in the manufacture of a medicament for the treatment of CFTR mediated diseases.
10 [0073] In an embodiment, said complexes are used for the treatment of CFTR mediated diseases.
[0074] CFTR mediated disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary 15 disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Naj jar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT
deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.
[0075] In an embodiment, a method of treatment of CFTR mediated diseases comprises administration of a therapeutically effective amount of complexes or pharmaceutical compositions as described herein.
[0076] In an embodiment, a method for reducing the therapeutically effective dosage of Ivacaftor compared to commercially available KALYDECOO comprises oral administration of a pharmaceutical composition as described herein.
[0077] In an embodiment, said complexes further comprise one or more additional active agents.
[0078] In an embodiment, said additional active agent is Lumacaftor, Tezacaftor or chosen from agents used for the treatment of CFTR mediated diseases.
[0079] In an embodiment said complex comprises Ivacaftor; or a combination of active compounds including Ivacaftor; a complexing agent chosen from copolymers of vinylpyrrolidone and vinyl acetate and sodium lauryl sulfate as an excipient; said complex characterized in that they possess at least one of the following properties:
a) is instantaneously redispersable in physiological relevant media;
b) is stable in solid form and in colloid solution and/or dispersion;
c) has an apparent solubility in water of at least 1 mg/mL;
d) has a PAMPA permeability of at least 0.4x10' cm/s when dispersed in FaSSIF
or FeSSIF
biorelevant media, which does not decrease in time at least for 6 month;
e) exhibits no observable food effect.
[0080] In an embodiment, said complex possesses at least two of the properties described in a) ¨
e).
[0081] In an embodiment, said complex possesses at least three of the properties described in a) ¨ e).
[0082] The novel complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
[0083] The expression Ivacaftor is generally used for Ivacaftor, or its salts or its derivatives.
[0084] In an embodiment, said complexation agent is chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyoxyl 15 hydroxystearate, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate.
[0085] In an embodiment, said complexation agents are copolymer of vinylpyrrolidone and vinyl acetate and poloxamer and said pharmaceutically acceptable excipient is sodium lauryl sulfate, and a) is characterized by infrared (ATR) spectrum having characteristic absorption peaks at 588 cm-', 628 cm-', 767 cm-', 842 cm-', 962 cm-', 1019 cm-', 1108 cm-', 1148 cm-', 1240 cm-', 1343 cm-', 1370 cm-', 1425 cm-', 1465 cm-', 1525 cm-', 1567 cm-', 1666 cm-' and 1732 cm';
and b) has characteristic Raman shifts at 552 cm-', 648 cm-', 826 cm-' ,845 cm-', 888 cm-', 932 cm-', 1026 cm-', 1062 cm-', 1082 cm-', 1129 cm-', 1140 cm-', 1208 cm-', 1233 cm-', 1262 cm-', 1284 cm 1, 1295 cm-', 1361 cm-', 1450 cm-', 1528 cm-', 1573 cm-', 1618 cm-', 1677 cm-', 1738 cm-', 746 cm 1, 2884 cm-' and 2936 cm-'.
[0086] In some embodiments, the compositions may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof. In some embodiments, active agents may include agents useful for the treatment of CFTR mediated diseases.
[0087] Another aspect of the invention is the complex formulations of the Ivacaftor with complexation agents and pharmaceutically acceptable excipients in which the complexation agents and pharmaceutically acceptable excipients preferably are associated or interacted with the Ivacaftor, such as the results of a mixing process or a continuous flow mixing process. In some embodiment, the structure of the complex Ivacaftor formulations is different from the core-shell type milled particle, precipitated encapsulated particles, micelles and solid dispersions.
[0088] The pharmaceutical composition of the invention can be formulated: (a) for administration selected from the group consisting of oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, and topical administration; (b) into a dosage form selected from the group consisting of liquid dispersions, gels, aerosols, ointments, creams, lyophilized formulations, tablets, capsules; (c) into a dosage form selected from the group consisting of controlled release formulations, fast melt formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations;
or (d) any combination of (a), (b), and (c).
[0089] The compositions can be formulated by adding different types of pharmaceutically acceptable excipients for oral administration in solid, liquid, local (powders, ointments or drops), or topical administration, and the like.
[0090] In an embodiment, the dosage form of the invention is a solid dosage form, although any pharmaceutically acceptable dosage form can be utilized.
[0091] Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders (sachet), and granules. In such solid dosage forms, the complex formula of Ivacaftor is admixed with at least one of the following: one or more inert excipients (or carriers):
(a) fillers or extenders, such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, erythritol, fructose, isomalt, lactitol, maltitol, maltose, maltodextrin, trehalose, xylitol, starches, microcrystalline cellulose, dicalcium phosphate, calcium carbonate, magnesium .. carbonate, magnesium oxide; (b) sweetening, flavoring, aromatizing and perfuming agents such as saccharin, saccharin sodium, acesulfame potassium, alitame, aspartame, glycine, inulin, neohesperidin dihydrochalcone, neotame, sodium cyclamate, sucralose, tagatose, thaumatin, citric acid, adipic acid, fumaric acid, leucine, malic acid, menthol, propionic acid, tartaric acid; (c) binders, such as cellulose derivatives, acrylic acid derivatives, alginates, gelatin, polyvinylpyrrolidone, starch derivatives, dextrose, dextrates, dextrin, maltose, maltodextrin; (d) disintegrating agents, such as crospovidon, effervescent compositions, croscarmellose sodium and other cellulose derivatives, sodium starch glycolate and other starch derivatives, alginic acid, certain complex silicates and sodium carbonate; (e) solution retarders, such as acrylates, cellulose derivatives, paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as polysorbates, cetyl alcohol and glycerol monostearate;
(h) lubricants such as talc, stearic acid and its derivatives, solid polyethylene glycols, sodium lauryl sulfate, glyceryl behenate, medium-chain triglycerides or mixtures thereof. For capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
[0092] In an embodiment, the dosage form of the invention is a liquid dispersible granules in a sachet form.
[0093] In an embodiment, said liquid dispersible granules comprise the complex formulation of Ivacaftor of the present invention together with pharmaceutically acceptable excipients selected from the group of fillers or extenders, such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, erythritol, fructose, isomalt, lactitol, maltitol, maltose, maltodextrin, trehalose, xylitol, starches, microcrystalline cellulose, dicalcium phosphate, calcium carbonate, magnesium carbonate, magnesium oxide.
[0094] In an embodiment, said liquid dispersible granules comprise the complex formulation of Ivacaftor of the present invention together with pharmaceutically acceptable excipients selected from the group of sweetening, flavoring, aromatizing and perfuming agents such as saccharin, saccharin sodium, acesulfame potassium, alitame, aspartame, glycine, inulin, neohesperidin dihydrochalcone, neotame, sodium cyclamate, sucralose, tagatose, thaumatin, citric acid, adipic acid, fumaric acid, leucine, malic acid, menthol, propionic acid, tartaric acid.
[0095] Further disclosed herein is a liquid dispersible granules comprising a. 25 ¨95 `)/0 stable complex formulation of Ivacaftor of the present invention;
b. 5 ¨75 A fillers or extenders;
c. 0.5 ¨25 A binders;
d. 0.1 ¨5 `)/0 sweetening, flavoring, aromatizing and perfuming agents;
wherein said liquid dispersible granules disperses within 3 min in liquid; and wherein said liquid dispersible granules obtained by wet or dry processes.
[0096] In an embodiment, said dispersion time is between 0.1 min and 10 min.
[0097] In an embodiment, said dispersion time is between 0.1 min and 5 min.
[0098] In an embodiment, said dispersion time is between 0.1 min and 3 min.
[0099] In an embodiment, said dispersion time is between 0.1 min and 1 min.
[00100]In an embodiment, Hausner-ratio of the said liquid dispersible granules of complex Ivacaftor formulations is less than 1.25 more preferably 1.00-1.18 5 [00101]In an embodiment, Hausner-ratio of the said liquid dispersible granules of complex Ivacaftor formulations is between 1.00 and 1.18.
[00102]In an embodiment, the particle size (D(90)) of said solid aggregates of complex Ivacaftor formulations is less than 2000 micrometers.
[00103]In an embodiment, 60-99 Yo of the said solid aggregates of complex Ivacaftor 10 formulations are in the size range of 160-1200 micrometers [00104]In an embodiment, said liquid is water, saliva, other physiologically or biologically acceptable fluid.
[00105]In an embodiment, the dosage form is chosen from a tablet and a capsule.
[00106] Advantages of the complex Ivacaftor formulations of the invention include, but are not 15 limited to (1) physical and chemical stability, (2) instantaneous redispersibility, (3) stability in colloid solution or dispersion in the therapeutic time window, (4) increased apparent solubility and permeability compared to the conventional Ivacaftor formulation, (5) no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex formulation in solution form, (6) good processability.
20 [00107] Beneficial features of the present invention are as follows: the good/instantaneous redispersibility of solid complex formulations of Ivacaftor in water, biologically relevant media, e.g. physiological saline solution, pH=2.5 HC1 solution, FessiF and FassiF
media and gastro intestinal fluids and adequate stability in colloid solutions and/or dispersion in the therapeutic time window.
[00108] In an embodiment, the complex Ivacaftor formulations of the present invention has increased apparent solubility and permeability. In some embodiments, the apparent solubility and permeability of the complex Ivacaftor formulae is at least 1 mg/mL and 0.5x10-6 cm/s, respectively.
[00109] In an embodiment, said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/mL, and has a PAMPA permeability of at least 0.5x10' cm/s.
[00110] The complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted solid.
[00111] The complexes of the present invention possess instantaneous redispersibility, has a PAMPA permeability of at least 0.4x10-6 cm/s when dispersed in water, FaSSIF
or FeSSIF
biorelevant media, which does not decrease in time at least for 6 month, exhibits no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Ivacaftor in solution form.
BRIEF DESCRIPTION OF THE DRAWINGS
[00112]The accompanying figures, which are incorporated and form part of the specification, merely illustrate certain embodiments of the present invention and should not be construed as limiting the invention. They are meant to serve to explain specific modes of the present invention to those skilled in the art.
Figure 1. Redispersibility of complex Ivacaftor compositions in ultrapurified water.
Figure 2. Redispersibility and PAMPA permeability of complex Ivacaftor compositions.
Figure 3. Redispersibility and PAMPA permeability of complex Ivacaftor compositions containing vinylpyrrolidone and vinylacetate copolymer (Kollidon VA 64) and poloxamer in different ratios.
Figure 4. Redispersibility and PAMPA permeability of complex Ivacaftor compositions containing vinylpyrrolidone and vinylacetate copolymer (Kollidon VA 64) itself and in combination with different poloxamers.
Figure 5. Physical appearance and stability of the produced complex Ivacaftor formula.
Figure 6. Physical appearance and stability of the produced complex Ivacaftor formula during the flow optimization.
Figure 7. Ivacaftor dissolution from granulated complex Ivacaftor formulation.
Figure 8. PAMPA permeability of complex Ivacaftor formulation in biorelevant media.
Figure 9. PAMPA permeability of complex Ivacaftor formulations stored at different condition and measured at different time points.
Figure 10. SEM photo of complex Ivacaftor formulation.
Figure 11. Raman spectra of crystalline Ivacaftor (A), freeze-dried Ivacaftor (B), complex Ivacaftor formulation (C), Placebo sample (prepared in the absence of Ivacaftor) (D), copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA64) (E), sodium lauryl sulfate (F) and poloxamer 338 (Pluronic F108) (G).
Figure 12. ATR spectra of crystalline Ivacaftor (A), amorphous Ivacaftor (B), complex Ivacaftor formulation (C), placebo (prepared in the lack of Ivacaftor) (D), copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA64) (E), sodium lauryl sulfate (F) and poloxamer 338 (Pluronic F108) (G).
Figure 13. XRD diffractogram of amorphous Ivacaftor and complex Ivacaftor.
Figure 14. PAMPA permeability of crystalline Ivacaftor, solid dispersion of Ivacaftor, complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA
64), poloxamer 338 (Pluronic F108)and sodium lauryl sulfate, complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 407 (Lutrol F127) and sodium lauryl sulfate and complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64) and sodium lauryl sulfate.
Figure 15. Comparative apparent solubility data of different Ivacaftor formulations.
Figure 16. Comparative dissolution tests of solid dispersion of Ivacaftor and complex Ivacaftor formulation.
Figure 17. Plasma concentrations of Ivacaftor following the oral administration of novel complex in the fasted and in the fed state to beagle dogs at 3 mg/kg dose (N=4).
Figure 18. Pharmacokinetic parameters following the oral administration of novel complex in the fasted and in the fed state to beagle dogs at 3 mg/kg dose (N=4).
EXAMPLES
[00113] Specific embodiments of the present invention will further be demonstrated by the following examples. It should be understood that these examples are disclosed only by way of .. illustration and should not be construed as limiting the scope of the present invention.
Selection of complex Ivacaftor formulations with improved material properties [00114] Several complexation agents and pharmaceutically acceptable excipients and their combinations were tested in order to select the formulations having instantaneous redispersibility as shown in Figure 1.
[00115]Examples that displayed an acceptable level of redispersibility was selected for further analysis.
[00116]PAMPA permeability of the selected formulations was measured in order to select the complex Ivacaftor formulation having the best in-vitro performance (Figure 2).
PAMPA
permeability measurements were performed as described by M. Kansi et al.
(Journal of medicinal .. chemistry, 41, (1998) pp 1007) with modifications based on S. Bendels et al (Pharmaceutical research, 23 (2006) pp 2525). Permeability was measured in a 96-well plate assay across an artificial membrane composed of dodecane with 20% soy lecithin supported by a PVDF
membrane (Millipore, USA). The receiver compartment was phosphate buffered saline (pH 7.0) supplemented with 1% sodium dodecyl sulfate. The assay was performed at room temperature;
incubation time was 4 hours in ultrapurified water, FaSSIF and FeSSIF, respectively. The concentration in the receiver compartment was determined by UV-VIS
spectrophotometry (VWR UV-3100PC Scanning Spectrophotometer).
[00117]Copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) itself and in combination with poloxamer 338 (Pluronic F108) or poloxamer 407 (Lutrol F127) were selected .. as complexation agents and sodium lauryl sulfate was selected as pharmaceutically acceptable excipient in order to prepare complex Ivacaftor formulations having improved material characteristics.
[00118]The ratio of the selected complexation agents and pharmaceutically acceptable excipients was optimized. Solid complexes of Ivacaftor were prepared by using different ratios of .. complexation agents and pharmaceutically acceptable excipients (Figure 3 and Figure 4).
Production of complex Ivacaftor formulations [00119] In order to select the best complex formulation, a solution mixture of Ivacaftor complex formula was prepared. 100 mL Solution 1 was prepared by dissolving 100 mg Ivacaftor and 300 mg copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 200 mg poloxamer 338 (Pluronic F108) in 100 mL tetrahydrofurane. The prepared Solution 1 was mixed with Solution 2 containing 25-100 mg sodium lauryl sulfate in 100 mL in order to produce complex Ivacaftor formulation. The appearance and stability of produced colloid solution were monitored. Based on the physical appearance and stability of the produced complex Ivacaftor formula in colloid solution, the best composition was selected for analytical investigations and further work (Figure .. 4 and Figure 5).
[00120] In order to select a complex formulation without poloxamer, a solution mixture of Ivacaftor complex formula was prepared. 100 mL Solution 1 was prepared by dissolving 100 mg Ivacaftor and 600 mg copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) in 100 mL tetrahydrofurane. The prepared Solution 1 was mixed with Solution 2 containing 300 mg sodium lauryl sulfate in 100 mL in order to produce complex Ivacaftor formulation. The composition was selected for analytical investigations and further work.
In order to select a complex formulation with poloxamer previously not mentioned, a solution mixture of Ivacaftor complex formula was prepared. 100 mL Solution 1 was prepared by dissolving 100 mg Ivacaftor and 300 mg copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 60-200 mg poloxamer 407 (Lutrol F127) in 100 mL
tetrahydrofurane. The prepared Solution 1 was mixed with Solution 2 containing 60-100 mg sodium lauryl sulfate in 100 mL in order to produce complex Ivacaftor formulation.
Continuous flow production of complex Ivacaftor formulations [00121]In order to make the production process industrially feasible, flow production was needed and process intensification was performed by increasing the concentrations of the starting solutions. For the experiments, 1:1 Solvent 1: Solvent 2 ratio was used. A
colloid solution of complex Ivacaftor formulation of the present invention was prepared by mixing process.
Solution 1 containing 500 mg Ivacaftor and 1500 mg copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 1000 mg poloxamer 338 (Pluronic F108) in 100 mL
tetrahydrofuran was mixed with aqueous Solution 2 containing 500 mg sodium lauryl sulfate in 100 mL ultrapurified water in different flow rates. The colloid solution of the complex Ivacaftor formulation was produced at atmospheric pressure and 20-50 C temperature. The appearance and stability of the produced colloid solution were monitored. Based on the physical appearance and stability of the produced complex Ivacaftor formulation in colloid solution, the best composition was selected for spray-drying experiments. Figure 6 summarizes the results.
[00122]The solidification of the colloid solution was performed by spray-drying technique. 5 5 mg/mL Ivacaftor, 15 mg/mL copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 10 mg/mL poloxamer 338 (Pluronic F108) in tetrahydrofurane and 5 mg/mL
sodium lauryl sulfate in water were chosen for starting concentrations. The ratio of the solutions was found to be optimal at 1:1 ratio. The colloid solution of the complex Ivacaftor formulation prepared by the optimal parameter sets was spray-dried (Yamato DL-410 / GAS410) in order to obtain solid 10 powder. The spray-drying process was optimized. The optimal production parameters were found to be Tõ,=95 C, V.r=0.8 m3/min, M18 mL/min, p=1 bar, Tout= 57-60 C.
[00123] The solidification of the colloid solution was performed by spray-drying technique. 5 mg/mL Ivacaftor, 30 mg/mL copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) in tetrahydrofurane and 15 mg/mL sodium lauryl sulfate in water were chosen for starting 15 concentrations. The ratio of the solutions was found to be optimal at 1:1 ratio. The colloid solution of the complex Ivacaftor formulation prepared by the optimal parameter sets was spray-dried (Yamato DL-410 / GAS410) in order to obtain solid powder. The spray-drying process was optimized. The optimal production parameters were found to be Tõ=95 C, V.r=0.8 m3/min, 1\418 mL/min, p=1 bar, Tout= 55-58 C.
20 [00124]The solidification of the colloid solution was performed by spray-drying technique. 5 mg/mL Ivacaftor, 15 mg/mL copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 10 mg/mL poloxamer 407 (Lutrol F127) in tetrahydrofurane and 5 mg/mL
sodium lauryl sulfate in water were chosen for starting concentrations. The ratio of the solutions was found to be optimal at 1:1 ratio. The colloid solution of the complex Ivacaftor formulation prepared by 25 the optimal parameter sets was spray-dried (Yamato DL-410 / GAS410) in order to obtain solid powder. The spray-drying process was optimized. The optimal production parameters were found to be Tõ,=95 C, V.r=0.8 m3/min, M18 mL/min, p=1 bar, Tout= 57-60 C.
[00125] The solidification of the colloid solution was performed by spray-drying technique. 5 mg/mL Ivacaftor, 15 mg/mL copolymer of vinylpyrrolidone and vinylacetate (Kollidon VA 64) and 3 mg/mL poloxamer 407 (Lutrol F127) in tetrahydrofurane and 3 mg/mL sodium lauryl sulfate in water were chosen for starting concentrations. The ratio of the solutions was found to be optimal at 1:1 ratio. The colloid solution of the complex Ivacaftor formulation prepared by the optimal parameter sets was spray-dried (Yamato DL-410 / GAS410) in order to obtain solid powder. The spray-drying process was optimized. The optimal production parameters were found to be Ttet=95 C, Va,r=0.85 m3/min, M18 mL/min, p=1 bar, Tout= 61 C.
Preparation of liquid dispersible granules comprising complex Ivacaftor formulation [00126]Liquid dispersible granules comprising the complex Ivacaftor formulations of the present invention can be obtained by wet or dry granulation processes.
[00127]Dry granulation process includes, but not limited to the slugging or roll compaction of the powder formulation of complex Ivacaftor into compacts and breaking of the compacts into granules with appropriate mesh size. The obtained granules can be blended with pharmaceutically acceptable excipients.
[00128]Dry granulation technique can be also applied on the powder blend of complex Ivacaftor formulations. Powder blend consists of the powder formulation of complex Ivacaftor and pharmaceutically acceptable excipients and prepared by blending of the powders. Slugging or roll compaction are used to manufacture compacts from the powder blend. Then the compacts are broken into granules with appropriate mesh size.
[00129]Wet granulation process covers the moisturizing of the powder formulations of complex Ivacaftor (direct granulation) or moisturizing the pharmaceutically acceptable excipients with aqueous solution of pharmaceutically acceptable binders and blending it with the powder formulations of complex Ivacaftor (indirect granulation). The particle size of the granules can be controlled by physical impact before and after the drying step.
[00130]Liquid dispersible granules of complex Ivacaftor formulation of the present invention were prepared by compacting appropriate amount of complex Ivacaftor powder blend using 0.5 ton load. The powder blend comprised of the solid formulation of the complex of Ivacaftor and pharmaceutically acceptable excipients selected from the group of sweetening, flavouring, aromatizing and perfuming agents. The height of the compact was found to be optimal between 0.8-1.0 mm. The compacts were broken up by physical impact to form granulates.
The particle size of the granules was controlled by sieving with appropriate mesh size to achieve 160-800 micrometres particle size.
Comparative solubility tests [00131] The apparent solubility of the granulated complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium-lauryl-sulfate was measured by UV-VIS spectroscopy at room temperature. The solid complex Ivacaftor formulations were dispersed in ultrapurified water in 1-10 mg/mL Ivacaftor equivalent concentration range. The resulting solutions were filtered by 100 nm disposable syringe filter. The Ivacaftor content in the filtrate was measured by UV-Vis spectrophotometry and the apparent solubility was calculated. The filtrate may contain Ivacaftor complex particles which could not be filtrated out using 100 nm pore size filter.
[00132]The apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64) and sodium lauryl sulfate and poloxamer 338 of the present invention was 0.991; 2.356; 4.924 and 9.463 mg/mL, when 1; 2.5;
5; and 10 mg/mL Ivacaftor equivalent formulations were dispersed in ultrapurified water, respectively.
[00133]Apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64) and sodium lauryl sulfate and poloxamer 338 was 9.463 mg/mL.
[00134] The apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), and sodium lauryl sulfate was measured by UV-VIS spectroscopy at room temperature. The solid complex Ivacaftor formulations were dispersed in ultrapurified water in 1 mg/mL Ivacaftor equivalent concentration range. The resulting solutions were filtered by 100 nm disposable syringe filter. The Ivacaftor content in the filtrate was measured by UV-Vis spectrophotometry and the apparent solubility was calculated.
The filtrate may contain Ivacaftor complex particles which could not be filtrated out using 100 nm pore size filter.
[00135]The apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64) and sodium lauryl sulfate was 0.936 mg/mL
when 1 mg/mL Ivacator equivalent formulation was dispersed in ultrapurified water.
[00136]Apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64) and sodium lauryl sulfate was 0.936 mg/mL.
[00137] The apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 407 (Lutrol F127) and sodium-lauryl-sulfate was measured by UV-VIS spectroscopy at room temperature.
The solid complex Ivacaftor formulations were dispersed in ultrapurified water in 1 mg/mL Ivacaftor equivalent concentration range. The resulting solutions were filtered by 100 nm disposable syringe filter. The Ivacaftor content in the filtrate was measured by UV-Vis spectrophotometry and the apparent solubility was calculated. The filtrate may contain Ivacaftor complex particles which could not be filtrated out using 100 nm pore size filter.
[00138]The apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 407 and sodium lauryl sulfate was 0.944 mg/mL when 1 mg/mL Ivacator equivalent formulation was dispersed in ultrapurified water.
[00139]Apparent solubility of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 407 and sodium lauryl sulfate was 0.944 mg/mL.
Dissolution test [00140]Ivacaftor dissolution was measured from the dry granulated formulation of the complex Ivacaftor containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate. The dissolution test was performed by dispersing the granulated complex Ivacaftor formulation in purified water at 1 mg/mL
concentrations. The dissolved amount was measured with UV-VIS
spectrophotometry after filtration with 0.1 1,1m pore size filter at different time points.
Dissolution of Ivacaftor from the granulated complex formulation was instantaneous, within 10 minutes 95 A of the Ivacaftor dissolved from the granulated complex Ivacaftor formulation (Figure 7).
Comparative in-vitro PAMPA assays [00141]PAMPA permeabilities of complex Ivacaftor formulations were measured in water, FaSSIF and FeSSIF media and were found to be above 0.4x10' cm/s in all tested media (Figure 8).
Stability of the solid formulation of complex Ivacaftor [00142] PAMPA permeability of the solid complex Ivacaftor formulations was used to monitor the physical stability of the formulation. PAMPA permeability was measured after storage of the complex Ivacaftor formulation at different conditions. 6 month storage at RT or 40 C relative humidity showed no significant decrease in the measured PAMPA
permeability under any of the conditions tested (Figure 9).
Structural analysis [00143]Morphology of complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate was investigated using FEI Quanta 3D scanning electron microscope. Complex Ivacaftor formulation of the present invention comprises spherical particles with particle size less than 50 nm (Figure 10).
[00144] Structural analysis was performed by using Vertex 70 FT-IR with ATR
and HORTB_A.
jobinYvon LabRAN HR UV-NTS-NM instruments.
[00145]Complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate or its pharmaceutical composition according to the invention is characterized by the Raman spectrum shown in Figure 11 and ATR spectrum shown in Figure 12.
[00146]Complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate or its pharmaceutical composition according to the invention is characterized by Raman shifts at 552 cm-1, 648 cm-1, 826 cm-1 ,845 cm-1, 888 cm-1, 932 cm-1, 1026 cm-1, 1062 cm-1, 1082 cm-1, 1129 cm-1, 1140 cm-1, 1208 cm-1, 1233 cm-1, 1262 cm-1, 1284 cm-1, 1295 cm-1, 1361 cm-1, 1450 cm-1, 1528 cm-1, 1573 cm-1, 1618 cm-1, 1677 cm-1, 1738 cm-1, 746 cm-1, 2884 cm-1 and 2936 cm-1.
[00147]Complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate or its pharmaceutical composition according to the invention is characterized by Raman shifts at 1082 cm-1, 1233 cm-1, 1284 cm-1, 1361 cm-1, 1528 cm-1, 1618 cm-1 and 1738 cm-1.
[00148]Complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate or its pharmaceutical composition is characterized by infrared (ATR) spectrum having characteristic peaks at 588 cm-1, 628 cm-1, 767 cm-1, 842 cm', 962 cm-1, 1019 cm-1, 1108 cm-1, 1148 cm-1, 1240 cm-1, 1343 cm-1, 1370 cm-1, 1425 cm-1, 1465 cm-1, 1525 cm-1, 1567 cm-1, 1666 cm-1 and 1732 cm-1.
[00149] Complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate or its pharmaceutical composition is characterized by ATR spectrum having characteristic peaks at 628 cm', 767 cm', 1108 cm', 1370 cm', 1465 cm-' and 1666 cm'.
5 [00150]The structure of the complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate was investigated by powder X-ray diffraction (XRD) analysis (Philips PW1050/1870 RTG powder-diffractometer). The measurements showed that the Ivacaftor in the complex formulations was XRD amorphous (Figure 13). Characteristic reflections on the diffractograms 10 of complex Ivacaftor formulation at 43 and 44 2Theta could be attributed to sample holder.
Comparative formulation study [00151]Ivacaftor is marketed in its solid dispersion form under the trade name of 15 KALYDECOO. Manufacturing of solid dispersion of Ivacaftor is described in US 20140221424 Al patent application. Using the manufacturing method described in the patent application, solid dispersion of Ivacaftor was prepared for comparative analytical assays. A
solvent system of methyl ethyl ketone (MEK) and water in the ratio of 90 wt `)/0 MEK : 10 wt `)/0 water was heated to 20-30 C in a reaction vessel equipped with a magnetic stirrer and thermal circuit. Into this 20 solvent system, hypromellose acetate succinate polymer (HPMCAS), sodium lauryl sulfate and Ivacaftor were added in the ratio of 19.5 wt `)/0 hypromellose acetate succinate : 0.5 wt `)/0 SLS:80 wt `)/0 Ivacaftor. The resulting mixture was solid formulated by spray-drying method.
[00152]Comparative analytical assays were used to investigate the physicochemical properties of the formulation prepared by solid dispersion technology and continuous flow mixing of the 25 present invention.
[00153]PAMPA permeability of the solid dispersion could not be detected in water and FaSSIF
media, while it was 70 A of the permeability of the complex Ivacaftor formulation of the present invention in FeSSIF (Figure 14).
[00154]Comparative apparent solubility measurements showed that the apparent solubility of 30 complex Ivacaftor formulation was at least 0.9 mg/mL, while apparent solubility of crystalline Ivacaftor, Ivacaftor in physical mixture, amorphous Ivacaftor in aqueous sodium lauryl sulfate solution and solid dispersion was below 0.1 mg/mL (Figure 15).
[00155]Comparative dissolution tests performed in water showed that the dissolution of Ivacaftor from the granulated complex formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate was instantaneous, within 10 minutes 90 A of the Ivacaftor dissolved from the granulated complex Ivacaftor formulation, while 0 A Ivacaftor dissolved from the solid dispersion in 60 minutes (Figure 16).
In-vivo pharmacokinetics /n-vivo PK test in large animals [00156]A beagle dog study using the granulated complex Ivacaftor formulation containing copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), poloxamer 338 (Pluronic F108) and sodium lauryl sulfate of the present invention at a dose of 3 mg/kg was performed in the fasted and fed state. The granulated complex formulation was administered to the animals orally as reconstituted dispersion. Food effect was only 1.1-fold (food effect in humans is 2-4-fold higher in the fed state, that is why the drug has to be taken after a high fat meal). Exposure was 1.25-times higher than the reference exposure. Cm ax was somewhat lower for the complex Ivacaftor formulation, however, for the more important parameter, C24,, the complex Ivacaftor was 1.4-times higher (Figure 17 and Figure 18).
[00157]From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
Claims (34)
1. A stable complex with improved physicochemical characteristics and enhanced biological performance comprising i. Ivacaftor or a salt thereof;
ii. at least one complexing agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymers of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate;
and iii. pharmaceutically acceptable excipients;
wherein said complex has a particle size is between 10 nm and 600 nm, and possesses one or more among the following features:
a) is instantaneously redispersible in physiological relevant media;
b) is stable in solid form and in colloid solution and/or dispersion;
c) has an apparent solubility in water is of at least 1 mg/mL;
d) has a PAMPA permeability of at least 0.4x10 -6 cm/s when dispersed in distilled water, which does not decrease in time at least for 6 months;
e) exhibits no observable food effect.
ii. at least one complexing agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymers of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate;
and iii. pharmaceutically acceptable excipients;
wherein said complex has a particle size is between 10 nm and 600 nm, and possesses one or more among the following features:
a) is instantaneously redispersible in physiological relevant media;
b) is stable in solid form and in colloid solution and/or dispersion;
c) has an apparent solubility in water is of at least 1 mg/mL;
d) has a PAMPA permeability of at least 0.4x10 -6 cm/s when dispersed in distilled water, which does not decrease in time at least for 6 months;
e) exhibits no observable food effect.
2. The complex as recited in Claim 1, wherein said complex has a particle size in the range between 10 nm and 400 nm.
3. The complex as recited in Claim 1, wherein said complex exhibits X-ray amorphous character in the solid form.
4. The complex as recited in Claim 1, wherein said complex possesses at least two of the properties described in a) ¨ e).
5. The complex as recited in Claim 4, wherein said complex possesses at least three of the properties described in a) ¨ e).
6. The complex as recited in Claim 5, wherein said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/naL, exhibits no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Ivacaftor in solution form.
7. The complex as recited in Claim 5, wherein said complex possesses instantaneous redispersibility, has a PAMPA permeability of at least 0.4x10 -6 cm/s when dispersed in water, FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 6 month, exhibits no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Ivacaftor in solution form.
8. The complex as recited in Claim 4, wherein said complex has an apparent solubility in water of at least 1 mg/mL and a PAMPA permeability of at least 0.5x10 -6 cm/s.
9. The complex as recited in Claim 5, wherein said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/mL, and has a PAMPA
permeability of at least 0.5x10 -6 cm/s.
permeability of at least 0.5x10 -6 cm/s.
10. The complex as recited in Claim 1, wherein said complexing agent is selected from the group consisting of copolymers of vinylpyrrolidone and vinylacetate and poloxamers.
11. The complex as recited in Claim 10, wherein said complexation agent is a copolymer of vinylpyrrolidone and vinylacetate.
12. The complex as recited in Claim 1, wherein said pharmaceutically acceptable excipient is chosen from sodium deoxycholate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
13. The complex as recited in Claim 12, wherein said pharmaceutically acceptable excipient is sodium lauryl sulfate.
14. The complex as recited in Claim 1 comprising a) Ivacaftor;
b) as complexing agent a copolymer of vinylpyrrolidone and vinylacetate, and optionally a poloxamer;
c) as an excipient sodium lauryl sulfate;
wherein said complex is characterized by infrared (ATR) spectrum having characteristic peaks at 588 cm-1, 628 cm-1, 767 cm-1, 842 cm-1, 962 cm-1, 1019 cm-1, 1108 cm-1, 1148 cm-1, 1240 cm-1, 1343 cm-1, 1370 cm-1, 1425 cm-1, 1465 cm-1, 1525 cm-1, 1567 cm-1, 1666 cm-1 and 1732 cm-1;
and is characterized by Raman shifts at 552 cm-1, 648 cm-1, 826 cm-1 ,845 cm-1, 888 cm-1, 932 cm-1, 1026 cm-1, 1062 cm-1, 1082 cm-1, 1129 cm-1, 1140 cm-1, 1208 cm-1, 1233 cm-1, 1262 cm-1, 1284 cm-1, 1295 cm-1, 1361 cm-1, 1450 cm-1, 1528 cm-1, 1573 cm-1, 1618 cm-1, 1677 cm-1, 1738 cm-1, 746 cm-1, 2884 cm-1 and 2936
b) as complexing agent a copolymer of vinylpyrrolidone and vinylacetate, and optionally a poloxamer;
c) as an excipient sodium lauryl sulfate;
wherein said complex is characterized by infrared (ATR) spectrum having characteristic peaks at 588 cm-1, 628 cm-1, 767 cm-1, 842 cm-1, 962 cm-1, 1019 cm-1, 1108 cm-1, 1148 cm-1, 1240 cm-1, 1343 cm-1, 1370 cm-1, 1425 cm-1, 1465 cm-1, 1525 cm-1, 1567 cm-1, 1666 cm-1 and 1732 cm-1;
and is characterized by Raman shifts at 552 cm-1, 648 cm-1, 826 cm-1 ,845 cm-1, 888 cm-1, 932 cm-1, 1026 cm-1, 1062 cm-1, 1082 cm-1, 1129 cm-1, 1140 cm-1, 1208 cm-1, 1233 cm-1, 1262 cm-1, 1284 cm-1, 1295 cm-1, 1361 cm-1, 1450 cm-1, 1528 cm-1, 1573 cm-1, 1618 cm-1, 1677 cm-1, 1738 cm-1, 746 cm-1, 2884 cm-1 and 2936
15. A complex according to either of Claims 1 or 13 comprising a complexation agent which is selected from the group of copolymer of vinylpyrrolidone and vinylacetate and optionally poloxamers and pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 1.0 weight % to about 95.0 weight % based on the total weight of the complex.
16. A complex according to either of Claims 1 or 13 comprising a complexation agent which is selected from the group of copolymer of vinylpyrrolidone and vinylacetate and optionally poloxamers and pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 50 weight % to about 95.0 weight % based on the total weight of the complex.
17. The complex as recited in Claim 1, wherein said complex has an increased dissolution rate.
18. A process for the preparation of a stable complex as recited in Claim 1, said process comprising the step of mixing a solution of Ivacaftor, and at least one complexing agent chosen from copolymers of vinylpyrrolidone and vinylacetate and optionally poloxamers, in a pharmaceutically acceptable solvent with an aqueous solution containing at least one pharmaceutically accepted excipient selected from the group of sodium deoxycholate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
19. The process as recited in Claim 18, wherein said process is performed in a continuous flow instrument.
20. The process as recited in Claim 19, wherein said continuous flow instrument is a microfluidic flow instrument.
21. The process as recited in Claim 18, wherein said pharmaceutically acceptable solvent is chosen from water, methanol, ethanol, isopropanol, n-propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, or combinations thereof.
22. The process as recited in Claim 21, wherein said pharmaceutically acceptable solvent is tetrahydrofuran.
23. The process as recited in Claim 18, wherein said solvents are miscible with each other and the aqueous solution comprises 0.1 to 99.9% weight of the final solution.
24. A pharmaceutical composition comprising the stable complex as recited in Claim 1 together with a pharmaceutically acceptable carrier.
25. The pharmaceutical composition as recited in Claim 24, wherein said composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration.
26. The pharmaceutical composition as recited in Claim 25, wherein said composition is suitable for oral administration.
27. The pharmaceutical composition comprising the complex according to Claim 26, wherein said composition comprises fast dissolving granules of the complex formulation according to Claim 1.
28. The pharmaceutical composition comprising the complex according to Claim 27, wherein said granules are suitable for the preparation of sachet dosage form.
29. A complex according to Claim 1 for use in the treatment of CFTR mediated diseases.
30. The complex for use according to claim 29, wherein said CFTR mediated disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C
deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT
deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.
deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT
deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.
31. A method of treatment of CFTR mediated diseases comprising administration of a therapeutically effective amount of the complex according to Claim 1 or the pharmaceutical composition according to Claim 24.
32. A stable complex comprising a) 5 ¨ 40% by weight of Ivacaftor or salt thereof;
b) 20 ¨ 80% by weight of a copolymer of vinylpyrrolidone and vinylacetate;
c) 5 ¨ 40 % by weight of sodium-lauryl-sulfate; and d) optionally 0 ¨ 50 % by weight of a poloxamer;
wherein said complex has a controlled particle size in the range between 10 nm and 600 nm;
and wherein said complex is not obtained via a milling process, high pressure homogenization process, encapsulation process or solid dispersion processes.
b) 20 ¨ 80% by weight of a copolymer of vinylpyrrolidone and vinylacetate;
c) 5 ¨ 40 % by weight of sodium-lauryl-sulfate; and d) optionally 0 ¨ 50 % by weight of a poloxamer;
wherein said complex has a controlled particle size in the range between 10 nm and 600 nm;
and wherein said complex is not obtained via a milling process, high pressure homogenization process, encapsulation process or solid dispersion processes.
33. The complex as recited in Claim 1, wherein said complex further comprises one or more additional active agents.
34. The complex as recited in Claim 26, wherein said additional active agent Lumacaftor, Tezacaftor or chosen from agents used for the treatment of CFTR mediated diseases.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1600270A HUP1600270A2 (en) | 2016-04-25 | 2016-04-25 | Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
HUP1600270 | 2016-04-25 | ||
PCT/IB2017/052370 WO2017187336A1 (en) | 2016-04-25 | 2017-04-25 | Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3021944A1 true CA3021944A1 (en) | 2017-11-02 |
Family
ID=89992148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3021944A Abandoned CA3021944A1 (en) | 2016-04-25 | 2017-04-25 | Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3448383A1 (en) |
JP (1) | JP2019515029A (en) |
CN (1) | CN109475548A (en) |
AU (1) | AU2017256180A1 (en) |
CA (1) | CA3021944A1 (en) |
HU (1) | HUP1600270A2 (en) |
IL (1) | IL262489A (en) |
WO (1) | WO2017187336A1 (en) |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
US7495103B2 (en) | 2004-06-24 | 2009-02-24 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
RS55940B1 (en) | 2005-12-28 | 2017-09-29 | Vertex Pharma | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
ES2845449T3 (en) | 2010-03-25 | 2021-07-26 | Vertex Pharma | Solid amorphous dispersion of (R) -1 (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) -N- (1- (2,3-dihydroxypropyl) -6-fluoro-2 (1-hydroxy-2-methylpropan-2-yl) -1h-indol-5yl) -cyclopropanecarboxamide |
BR112013004130A2 (en) | 2010-08-27 | 2016-07-05 | Vertex Pharma | pharmaceutical composition and administrations thereof |
JP2015511583A (en) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Pharmaceutical composition and its administration |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
WO2014071122A1 (en) | 2012-11-02 | 2014-05-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr mediated diseases |
JP6146990B2 (en) | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | Deuterated CFTR enhancer |
US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
EP2951158B1 (en) | 2013-01-31 | 2019-05-29 | Glenmark Pharmaceuticals Limited | Process for the preparation of ivacaftor and solvates thereof |
US9573902B2 (en) | 2013-02-15 | 2017-02-21 | Laurus Labs Private Ltd. | Process for the preparation of Ivacaftor and its intermediates |
CN104030981A (en) | 2013-03-06 | 2014-09-10 | 上海特化医药科技有限公司 | Preparation method and intermediate of Ivacaftor |
HUP1300646A2 (en) * | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
EP3068392B9 (en) | 2013-11-12 | 2021-08-04 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
HUP1300647A2 (en) * | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
WO2015071841A1 (en) * | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
AU2014351028B2 (en) | 2013-11-13 | 2018-07-12 | Apotex Inc. | Solid forms of Ivacaftor and processes for the preparation thereof |
HUP1400075A2 (en) * | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical composition containing them |
PL3424534T3 (en) | 2014-04-15 | 2021-11-22 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
CN104725314A (en) | 2015-03-23 | 2015-06-24 | 上海皓元化学科技有限公司 | New crystal form of Ivacaftor and preparation method thereof |
CA3021752A1 (en) * | 2015-06-11 | 2016-12-15 | Aizant Drug Research Solutions Private Limited | Nanoparticulate ivacaftor formulations |
-
2016
- 2016-04-25 HU HU1600270A patent/HUP1600270A2/en unknown
-
2017
- 2017-04-25 AU AU2017256180A patent/AU2017256180A1/en not_active Abandoned
- 2017-04-25 CA CA3021944A patent/CA3021944A1/en not_active Abandoned
- 2017-04-25 WO PCT/IB2017/052370 patent/WO2017187336A1/en active Application Filing
- 2017-04-25 CN CN201780039667.4A patent/CN109475548A/en active Pending
- 2017-04-25 JP JP2019506560A patent/JP2019515029A/en not_active Withdrawn
- 2017-04-25 EP EP17726697.0A patent/EP3448383A1/en not_active Withdrawn
-
2018
- 2018-10-21 IL IL262489A patent/IL262489A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL262489A (en) | 2018-12-31 |
WO2017187336A4 (en) | 2017-12-21 |
EP3448383A1 (en) | 2019-03-06 |
AU2017256180A1 (en) | 2018-12-13 |
HUP1600270A2 (en) | 2017-10-30 |
JP2019515029A (en) | 2019-06-06 |
WO2017187336A1 (en) | 2017-11-02 |
CN109475548A (en) | 2019-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10675277B2 (en) | Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
US20200022969A1 (en) | Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them | |
US20210228489A1 (en) | Compositions for treating cystic fibrosis | |
US20150010628A1 (en) | Pharmaceutical composition and administrations thereof | |
TW201922730A (en) | Crystalline Forms and compositions of CFTR modulators | |
US10688110B2 (en) | Complexes of Celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
KR102684756B1 (en) | Pharmaceutical composition for oral administration containing enzalutamide | |
AU2017256184A1 (en) | Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them | |
CA3042888A1 (en) | Pharmaceutical formulation containing tadalafil | |
US20190388408A1 (en) | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
CA3021944A1 (en) | Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
CA3021941A1 (en) | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
WO2015199115A1 (en) | Pharmaceutical composition for oral administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20221026 |